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Abstract 
Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disorder characterized 
by abundant immune complex (IC) deposition, with nephritis being a major cause of morbidity 
and mortality. Yet, IC deposition alone is not sufficient for disease development suggesting that 
additional factors dictate the propensity for developing target organ injury. Genome-wide 
association studies have identified polymorphisms in the leukocyte integrin Mac-1 
(CD11b/CD18, ITGAM) that associate with lupus nephritis. Although Mac-1 promotes 
inflammation by triggering leukocyte recruitment and cytotoxic functions, there is emerging 
evidence that it may also serve protective roles under certain conditions. We demonstrate that 
Mac-1 deficiency in the context of the uniquely human FcγRIIA, a receptor that binds IgG-IC, 
promotes susceptibility to lupus nephritis in two independent animal models. Analysis of renal 
tissue and intravital microscopy revealed that Mac-1 modulates neutrophil recruitment by 
FcγRIIA. The SLE-associated variant of Mac-1 rs1143679 (R77H), results in reduced Mac-1 
functions, but the underlying mechanism remains undefined. CD18 integrin mediated adhesion is 
a multistep process that begins with affinity changes for ligand via transmission of allosteric 
signals. Moreover, mechanical forces (e.g. shear flow) paradoxically increase the lifetime of 
integrin-ligand bonds, referred to as “catch-bonds”.  Here, we show that neutrophils expressing 
Mac-1 R77H, and blocking antibodies to the extracellular β-propeller domain in which it resides, 
have markedly impaired Mac-1 adhesion to ligand under shear flow. R77H-expressing cells 
exhibit a shift in equilibrium towards a bent conformation, a lower affinity and on- and off- rate 
for ligand, and an inability to form catch-bonds. Additional mutants and activating antibodies 
reveal that R77H prevents allosteric signal transmission to the αI-domain required for productive 
ligand binding.  
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Together, our data indicate that Mac-1 is a key regulator of neutrophil FcγRIIA-dependent 
responses triggered by ICs, which may be exploited therapeutically to limit tissue injury in the 
context of SLE. Our findings also demonstrate, for the first time, the physiological importance of 
integrin allostery and catch bonds, and provide a potential molecular mechanism by which R77H 
reduces Mac-1 functions and thus increases the risk for SLE.  
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Chapter 1. Introduction 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects more than 
250,000 Americans. It shows a strong predilection for women (in a 9:1 ratio) and usually 
develops during the childbearing age (1). It may target multiple organs including the kidneys, 
joints, skin, and the central nervous system. There is compelling evidence that genes contribute 
to the development of SLE. The importance of environmental factors is also well recognized (2).  
Patients with SLE develop a chronic autoimmune response manifested by the presence of 
autoantibodies and activated T cells. The factors that enable the development and perpetuation of 
autoimmunity in SLE are poorly understood. Current paradigms suggest that the combination of 
multiple risk alleles allow the initiation and development of SLE when the immune system is 
triggered by environmental factors such as infections, hormones, and an increased burden of 
apoptotic cell debris (2). The pathways through which risk alleles contribute to disease are 
mostly unknown. However, several phenotypic alterations in cells from both the innate and 
adaptive immune systems have been documented in SLE patients (3). For example, T cells 
display an enhanced activation state manifested by aberrant cytokine production (e.g. increased 
IL-17 and decreased IL-2 secretion) and provide increased levels of help to B cells. Defects in 
the negative selection process of B cells have been proposed to explain an increased abundance 
of autoreactive B cells in the B cell repertoire of patients with SLE. This factor, along with 
increased T cell help probably underlies the production of a large array of autoantibodies against 
soluble and cellular components (mostly against intra nuclear antigens). Dendritic cells (DCs) 
and macrophages have also been shown to have an overstimulated phenotype and function that 
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contributes to the production of inflammatory cytokines (e.g. IFNα) that further amplify the 
autoimmune response (4). 
A consequence of the chronic autoimmune response of patients with SLE is the production and 
tissue deposition of immune complexes (IC). Deposition of IC is thought to be the main trigger 
of glomerulonephritis and other SLE manifestations (5,6). In fact, IC and complement deposition 
is a widespread finding in the dermo-epidermal interphase (lupus band) in the skin (7) and in the 
mesangial space of the glomeruli of patients with SLE (8-10). However, IC deposition can be 
observed in healthy skin (7) of patients and in kidneys that lack any sign of inflammation (8-10), 
suggesting that their mere presence cannot fully account for the development of local 
inflammation. In this regard, it is increasingly recognized that chronic autoimmunity in patients 
with SLE does not suffice for target organ inflammation. For example, development of 
autoantibodies precedes by several years the initiation of clinically relevant disease in patients 
with SLE (11). Moreover, the clinical heterogeneity of the disease indicates that factors 
independent of those that control the autoimmune response govern target organ involvement 
because patients with similar autoantibody profiles can present with completely different disease 
manifestations (12).    
ICs can induce inflammation by activating the classical pathway of complement and engaging 
Fcγ receptors (FcγRs) in effector cells. Some products of complement activation (i.e. the 
anaphylatoxins C3a, C4a, and C5a) promote cell recruitment and activation (13). Others decorate 
the ICs (C1q and iC3b) and facilitate their deposition and recognition by effector cells. Both 
neutrophils and macrophages are potently activated by ICs and are observed within inflammatory 
infiltrates in lesions from patients with SLE (14).  
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The overall aim of this project was to study the molecular mechanisms that regulate the 
inflammatory response to IC deposition focusing on the role of neutrophils, human FcγRs and 
the integrin Mac-1 (CD11b/CD18), a known complement receptor, in this process. The 
understanding of these mechanisms is relevant not only to SLE, but may also apply to other IC-
dependent diseases such as postinfectious glomerulonephritis and cryoglobulinemia. 
 
Neutrophils rapidly respond to inflammatory cues and efficiently eliminate pathogens through 
the production of reactive oxygen species (ROS) and the release of proteolytic enzymes. 
Neutrophil activation modulates the ensuing effector responses through the production of 
chemokines and cytokines. Neutrophils contribute to the inflammatory response in patients with 
SLE, likely in response to deposited ICs formed by IgG but there is no direct evidence for this. 
The role of FcγRs in diseases that are initiated by antibodies is supported by the fact that mice 
deficient in the γ chain (γ-/-), which lack all the activating FcγRs, are protected in many IC-
mediated models (e.g. models of lupus, arthritis, acute and progressive glomerulonephritis). 
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Because the repertoire of FcγRs is fundamentally different in human and mouse neutrophils 
(Figure 1), the role of the human neutrophil receptors cannot be adequately evaluated in murine 
models. Dr. Mayadas’ lab has demonstrated that neutrophil-selective expression of the uniquely 
human FcγRIIA restores the susceptibility to IC-mediated inflammation (i.e. arthritis and 
glomerulonephritis) in γ-/- mice (15,16).   
Mac-1 is a member of the integrin family of cell surface receptors, expressed only in leukocytes. 
It is a heterodimer formed by an α-chain (CD11b) coupled to a β-chain (CD18). Mac-1 has 
multiple ligands including the complement fragment C3 (iC3b), the intracellular adhesion 
molecule-1 (ICAM-1), and the platelet receptor GPIbα. Several proinflammatory functions have 
been attributed to Mac-1, mainly due to its capacity to promote adhesion-dependent functions 
(e.g. leukocyte recruitment to sites of inflammation, induction of phagocytosis of complement-
opsonized particles, generation of ROS). However, Mac-1 has also been shown to have functions 
that oppose inflammation. For example, it regulates neutrophil apoptosis, it participates in the 
clearance of apoptotic cells and in the uptake of soluble ICs in vitro (17), and negatively 
regulates IFNα and TLR responses (18,19). In murine models of autoimmunity (e.g. lupus 
nephritis, asthma, and arthritis) disease severity worsens in the absence of Mac-1 (20-22). 
Additionally, a polymorphism in Mac-1 has been associated with SLE (23,24). This single 
nucleotide polymorphism (SNP) has been reported to decrease Mac-1 binding to its ligands (25), 
supporting the idea that engagement of Mac-1 results in immune-regulatory properties.  
The general hypothesis of this project was that Mac-1 plays an immunomodulatory role by 
regulating neutrophil function in the context of an autoimmune disease. In support of this 
hypothesis, I have shown in two independent, novel mouse models of lupus that mice that 
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express human FcγRIIA selectively on neutrophils develop nephritis only when the mice lack 
Mac-1. In the first model, I demonstrate that passive transfer of serum from SLE patients induces 
nephritis in mice expressing the human FcγRIIA only when the mice additionally lack Mac-1. In 
the second model, a chronic autoimmune response results in the generation of lupus nephritis in 
the context of FcγRIIA, and the severity markedly increases in absence of Mac-1. In both 
models, Mac-1 deficiency results in FcγRIIA-dependent renal neutrophil accumulation. This 
potential immunomodulatory function of Mac-1 might be relevant for human disease, since the 
R77H variant of Mac-1 that strongly associates with SLE impairs Mac-1 functions. We provide a 
potential mechanism whereby the R77H reduces Mac-1 function: it impairs Mac-1 mediated 
adhesion to ligand under shear flow conditions, shifts the integrin equilibrium between the bent 
versus extended conformation, and prevents the formation of catch-bonds, a process that 
increases the life-time of the integrin-ligand bond when the leukocyte is exposed to mechanical 
forces such as shear flow.  
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Chapter 2.  Human lupus serum induces neutrophil mediated organ damage in mice that is 
enabled by Mac-1 deficiency 
 
Note: The contents of the sections I-IV have been published (26) 
 
I. Introduction 
SLE is a systemic autoimmune disease that affects multiple organs including the kidney, joints 
and skin, with development of nephritis being one of the most serious complications of this 
disorder. SLE is characterized by loss of tolerance to self-antigens and high titers of circulating 
autoantibodies (11). In mice, deletion of the common Fcγ-chain (γ-/-) that results in the loss of 
activating FcγRs, protects lupus-prone New Zealand Black/New Zealand White mice from 
spontaneously developing lupus nephritis (27,28). Yet, there is little direct evidence that immune 
complexes (ICs) are causative as there are no reports that the passive transfer of SLE sera 
induces disease. Moreover, autoantibodies to classical lupus antigens such as dsDNA are not 
sufficient for development of nephritis in lupus-prone mouse strains and renal biopsies of SLE 
patients without clinically evident nephritis can exhibit IC deposition. Thus factors in addition to 
ICs likely dictate the propensity to develop target organ damage the identification of which 
remains a central question in the field (5,29,30).  
Human genome-wide association studies have shown that small variations in a large number of 
genes are associated with lupus. The current paradigm assumes that these traits modulate, 
through different pathways, the expression of disease in lupus. Variations in one of these genes is 
the leukocyte integrin Mac-1 (ITGAM, CD11b/CD18) (4), a member of the leukocyte CD18 
integrin family of adhesion molecules that are obligate heterodimers of unique CD11 subunits 
paired with a common CD18 chain. Mac-1 has multiple ligands including complement fragment 
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iC3b, and ICAM-1 on the endothelium (31), and the Mac-1 R77H polymorphism associated with 
lupus (24) leads to a reduction in its binding to both these ligands (25). The question remains as 
to whether Mac-1, which typically promotes inflammation and host defense (31) plays a role in 
the pathogenesis of lupus. The prevailing view is that Mac-1 on macrophages clears circulating 
ICs (24), although there is no direct evidence of this. Likewise, polymorphisms in human 
FcγRIIA and FcγRIIIB are associated with lupus through mechanisms that remain largely unclear 
(4). The physiological roles of the uniquely human neutrophil FcγRs, which structurally differ 
from their mouse counterparts (13,32), have been addressed in genetically engineered mice. 
Expression of the single polypeptide FcγRIIA, containing an ITAM, and the glycosyl-
phosphatidyl-inositol (GPI)-anchored FcγRIIIB selectively on neutrophils of Fcγ-chain deficient 
mice (IIAγ-/-, IIAIIIBγ-/-), restored susceptibility of γ-/- animals to progressive anti-glomerular 
basement membrane (GBM) nephritis and K/BxN serum-induced arthritis (15,16). Although 
both human FcγRs promoted neutrophil accumulation, only FcγRIIA alone induced tissue injury 
likely through their known ability to promote neutrophil cytotoxic functions (15). 
Difficulty in understanding the underlying mechanisms of SLE arises from the multifactorial 
influences on disease course including environmental, infectious and hormonal factors, the 
association of lupus with abnormalities at all levels of the immune system and the clinical 
heterogeneity of the disease (4). The disparate disease courses in SLE likely converge into a 
common route of end organ damage. Here, in a new model of lupus induced by the passive 
transfer of human SLE sera we provide direct evidence that SLE ICs are pathogenic, show a 
central role for neutrophils in target organ damage and demonstrate that two molecules, FcγRIIA 
and Mac-1, determine the capacity of ICs to cause tissue damage. In addition, these results 
coupled with the analysis of neutrophil behavior by intravital microscopy revealed a new 
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regulatory role for Mac-1 in FcγRIIA mediated neutrophil recruitment following deposition of 
circulating ICs. 
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II. Materials and Methods  
Mice  
Fcγ-chain deficient mice, human FcγRIIA and FcγRIIIB-expressing γ-chain deficient mice (IIAγ-
/- or IIAIIIBγ-/-), Mac-1-deficient mice (Mac-1-/-) and CD18-deficient mice (CD18-/-) have been 
described (15,33-35).  Mac-1 deficient mice were bred with IIAγ-/- or IIAIIIBγ-/- mice to generate 
IIAγ-/-Mac-1-/- and IIAIIIBγ-/-Mac-1-/- animals or with wild type mice to generate IIAγ+/+Mac-1-/- 
and IIAγ+/+ mice. Mice were bred in a specific pathogen free facility. Age and gender matched 
mice 8–12 weeks old were used in all experiments. The Harvard Medical School Animal Care 
and Use Committee approved all procedures used in this study. 
Passive transfer of human SLE sera or rabbit anti-GBM antibody  
For the human SLE sera transfer model, mice were injected subcutaneously in both flanks with 
2.5 µg of human IgG (Jackson ImmunoResearch Labs) in complete Freund’s adjuvant (Thermo 
Scientific and Difco) on day -3. On days 0 and 2, 200µL of sterile serum was injected 
intravenously. For induction of nephrotoxic nephritis, mice were given rabbit IgG in CFA at day 
-3 in the footpad and rabbit αGBM antisera at day 0 as described (36) and urine and kidneys 
were collected at day 21.  
Human sera samples  
Human serum samples were obtained from the Lupus Clinic at the Beth Israel Deaconess 
Medical Center or Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Patients 
with SLE were diagnosed according to the classification criteria of the American College of 
Rheumatology (ACR). The inclusion criteria for SLE patients were patients who fulfilled ≥ 4 of 
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11 ACR criteria for SLE and that at the time of the first blood draw, had active disease (i.e. SLE 
disease activity index (SLEDAI) ≥6). Normal serum was obtained from healthy individuals 
matched for age, gender and ethnicity. At the time of serum collection, all individuals showed no 
signs or symptoms of infection. Informed consent was obtained from all patients and healthy 
donors under a BIDMC Institutional Review Board (IRB) approved protocol. Unless indicated, 
all experiments were performed using serum from SLE patient “A”. 
Disease evaluation 
Functional assessment of renal damage: Spot urine samples were collected and urine albumin 
and creatinine were evaluated by ELISA (Bethyl Labs) and a chemical assay (Cayman Chemical 
Company) respectively (15) and expressed as a ratio of urine albumin to creatinine. 
Clinical scoring of arthritis: Mice were evaluated every other day after induction of disease. 
Inflammation of each limb was scored as reported previously (37): 0, no evident inflammation; 
1, redness or swelling of one toe; 2, redness or swelling of >1 toe; 3, ankle or tarsal-metatarsal 
involvement; 4, redness or swelling of the entire paw.  
Histological assessment of tissue injury: Tissue sections were blindly evaluated. Histological 
score included endocapillary proliferation, leukocyte infiltration and crescents, as previously 
described (38). For joint lesions, histological scores reflected leukocyte infiltration, synovial 
thickening, and cartilage and bone erosion. 
Histological studies           
Kidneys were fixed in formalin and paraffin-embedded, or frozen in OCT medium and 5µM 
sections were prepared. Toe specimens were fixed in 4% paraformaldehyde and decalcified with 
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modified Kristensen’s solution. After dehydration, the tissues were embedded in paraffin and 5 
µm sections were made (39).  
Immunohistochemistry: For kidneys, periodic acid-Schiff, H&E and dichloroacetate esterase (to 
identify neutrophils) on paraffin-embedded sections were performed as described (40). 
Neutrophils in 100 glomerular cross-sections were quantified and presented as neutrophils per 
glomerular cross-section. Immunohistochemistry on frozen sections was performed using a two-
layer peroxidase method. Sections were immunostained with anti-F4/80 for macrophages 
(BioLegend), anti-CD3 (Serotech) for T cells, anti-C1q (Hycult Biotech) for C1q deposition and 
counterstained with Gill Hematoxylin No.2 (NewComerSupply Inc.). Tissue area occupied by 
macrophages or glomerular C1q deposition in four 20x consecutive fields was quantified using 
ImagePro. Sections of paraffin-embedded toes were stained with H&E and 
immunohistochemistry was performed with anti-NIMP-R14 (Abcam) for neutrophil 
quantification, anti-F4/80 (BioLegend) for macrophages, anti-CD3 (Serotech) for T cells or anti-
human IgG (Invitrogen). The total number of neutrophils in a toe cross-section was counted and 
divided by the total tissue area in each section, using ImagePro. 
Immunofluorescence: Human and mouse IgG deposition were evaluated on frozen sections using 
anti-human IgG or anti-mouse IgG (Invitrogen) Alexa fluor 488-conjugated antibodies, 
respectively. Deposition of C3 was evaluated using a FITC-conjugated anti-C3 antibody 
(ICN/CAPPEL). Images of at least 15 glomeruli per mouse were captured and glomerular 
fluorescence intensity was measured using the acquisition and analysis software Metamorph 
(Molecular Devices). To evaluate human IgG subclasses, immunofluorescence was performed 
using anti-human IgG1, IgG2, IgG3, and IgG4 antibodies (The Binding site) followed by an anti-
sheep DyLight-488 conjugated antibody (Jackson ImmunoResearch Laboratories Inc.).  
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Electron microscopy: Kidney samples were taken 10 days after injection of SLE sera and 
processed using standard techniques. 
Generation of a K562 stable cell line and analysis of binding to ICAM-1  
The R77H mutation was introduced into human CD11b DNA by standard PCR techniques. K562 
cells were transfected with WT or mutant (R77H) CD11b and CD18 plasmids by electroporation 
and confirmed by sequencing. Single cell sorting was used to select CD11b positive cells. Cells 
were cultured in RPMI 1640 media supplemented with 10% heat inactivated FBS, under constant 
selection using G418 (500µg/mL, Invivogen). CD11b expression was assessed by FACs analysis 
using anti-human CD11b-PE labeled antibody (BD Pharmingen). To evaluate K562 cell binding 
to ICAM-1Fc, cells were treated with 1mM MnCl2 for 10min in HEPES buffer and drawn across 
a coverslip containing immobilized ICAM-1-Fc (15µg/mL, R&D) under 0.1dynes/cm2 shear 
flow. The number of cells bound in 4 different fields was quantified every 2 minutes over a 10 
min period.  
IgG depletion and quantification of human IgG  
SLE serum was incubated with Protein A/G coated agarose beads (Thermo Scientific) or control 
agarose beads. Depletion was determined by measuring human IgG by ELISA (Bethyl Labs). 
Human immune complexes were quantified in human and mouse serum using an ELISA kit with 
C1q as the capture element (ALPCO Immunoassays). Due to cross-reactivity with mouse IgG, an 
anti-human HRP antibody (Bethyl Labs) was used as the secondary antibody for the 
quantification of human ICs in murine serum samples.  
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Macrophage depletion using clodronate liposomes 
Mice were given an intraperitoneal injection of 500µL of liposomes containing clodronate or 
PBS (41) on day -5 before the first SLE injection, followed by 200µL every 5 days. Tissue was 
harvested at day 10 or 14 after SLE sera injection. Macrophage depletion was confirmed by 
immunohistochemistry of kidneys and spleen using anti-F4/80 antibody. 
Intravital microscopy evaluation of Reverse Passive Arthus reaction in the cremaster 
muscle  
Rabbit IgG anti-bovine serum albumin (BSA) antibody (200μg/300μL; Sigma-Aldrich, St. Louis, 
MO) was injected intrascrotally, followed by an intravenous injection of BSA (300µg/100μL; 
Sigma-Aldrich, St. Louis, MO). After 3hrs, leukocyte recruitment in the cremaster of 
anesthetized mice was evaluated by intravital microscopy as previously described (15). Four 
venules per mouse were analyzed. Leukocyte rolling velocities were measured by tracking single 
leukocytes (10/venule) over several frames and calculating the distance moved per unit time 
(μm/s). Adherent leukocytes were defined as cells remaining stationary for 30 seconds and were 
expressed as the number of cells/mm2 of venule.  
MIP-2 was locally applied as previously described (42). Briefly, injections were done using a 
beveled glass pipette of 1mm outer diameter mounted on a manual micromanipulator (MM-33) 
(Warner Instruments, Hamden, CT). The tip was filled with 100 nmol/L of MIP-2 (US 
Biologicals). The pipette was placed and the number of rollers across a perpendicular line and 
adherent cells (Ab) in a 200 µm segment of the venule was recorded over a 1 minute period. 
Next, air pressure was applied to the pipette, to trigger the injection of MIP-2 (less than 1 µL). 
Successful injection was verified by the presence of swelling of the interstitial tissue surrounding 
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the pipette tip. The process of injection, and the following minute were recorded. The number of 
cells that were adherent after MIP-2 injection (Aa) was evaluated. The ∆ adherent cells, which is 
the percent of rollers that adhered in response to MIP-2 injection, was calculated using the 
following equation: (Aa-Ab)/ #rollers X100. 
Statistical analysis 
Data are expressed as mean ± SEM. For proteinuria data, the line represents the median of the 
group. Differences were determined by Mann–Whitney test. For group analysis, one-way 
ANOVA was used for proteinuria data and two-way ANOVA was used for the cellular 
infiltration data. When significant differences were shown, data were subjected to Mann–
Whitney test or Bonferroni test respectively for comparison between two mouse strains. P values 
<0.05 were considered significant.  
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III. Results 
Human SLE serum induces nephritis in mice that express neutrophil human FcγRs and 
lack Mac-1 
Human SLE serum was obtained from patients that had active disease (SLEDAI≥6) and no 
clinical evidence of infection. Gender and race matched healthy individuals served as controls. 
Mice preimmunized with human IgG/CFA received two intravenous injections of SLE sera at 
day 0 and day 2. Nephritis was monitored by analyzing albumin leakage in the urine over a 21 
day period. SLE serum from patient “A” caused marked proteinuria in mice that expressed 
human FcγRs (hFcγRs) only when the mice additionally lacked Mac-1 (IIAγ-/-Mac-1-/- and 
IIAIIIBγ-/-Mac-1-/-) (Fig. 2A). Proteinuria peaked at day 14 (Sup. Fig. 1A). Mac-1-deficient mice 
expressing FcγRIIA alone, without FcγRIIIB exhibited significant proteinuria suggesting that 
this hFcγR was sufficient for disease development (Fig. 2A). No proteinuria was observed in 
Mac-1-sufficient mice expressing hFcγRs (IIAγ-/- or IIAIIIBγ-/-), Mac-1-deficient mice without 
hFcγRs (γ+/+Mac-1-/-) or wild-type animals (Fig. 2A). Surface expression of human FcγRs and the 
sister CD18 integrin, LFA-1 was similar in Mac-1 deficient and sufficient groups (Sup. Fig. 1B). 
Any effect of γ-chain deficiency superimposed on Mac-1 deficiency on disease susceptibility 
was ruled out as SLE serum induced nephritis in mice that expressed hFcγRIIA, lacked Mac-1, 
and were γ-chain sufficient (Fig. 2B). 
Mouse anti-human IgG was detected in the serum (Sup. Fig. 1C) and in the kidney (Fig. 2C) 
after SLE sera transfer but this was minimal compared to that in wild-type mice subjected to 
anti-glomerular basement membrane (nephrotoxic) nephritis (Fig. 2C), a widely used model of 
immune-mediated disease induced by preimmunization with rabbit IgG/CFA followed by 
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transfer of rabbit anti-glomerular basement membrane serum (43). Importantly, mouse anti-
human IgG levels in both the serum and renal tissue were similar in disease susceptible and non-
susceptible mice (Sup. Fig. 1C and Fig. 2C). Although a role for mouse anti-human IgG and/or 
ICs formed from human IgG reacting with antigens in the mouse serum cannot be formally ruled 
out it is unlikely to be critical for disease development for the following two reasons. First, SLE 
sera induced nephritis in the absence of preimmunization with CFA/human IgG (data not shown) 
albeit disease was more variable. Second, human FcγRs and thus by inference, human IgG is 
required for development of nephritis. In the anti-GBM murine model rabbit IgG triggers a 
robust murine anti-rabbit reaction, nonetheless, tissue injury is largely independent of the 
humoral response (44). We propose that as is known for other autoimmune models, activation of 
the innate immune response by CFA in our SLE model may be important independent of the 
adaptive immune response (45).  
Histopathological and electron microscopy analyses of renal tissue from human SLE sera-treated 
mice were undertaken. Congruent with proteinuria, 
glomerular damage and inflammation were observed 
only in hFcγR+γ-/-Mac-1-/- animals (Fig. 2D, E) and 
were associated with mesangial deposits of ICs (Fig. 
2E). Together these data suggest that Mac-1 
deficiency enables SLE-induced kidney damage. 
This may have relevance to human disease since the 
R77H polymorphism in the ITGAM gene (that 
encodes the CD11b chain of Mac-1) associated with 
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SLE abrogates the capacity of Mac-1 expressed in a cell line (Fig. 3A), to bind its ligand ICAM-
1 (Fig. 3B).  
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Pathogenicity of SLE serum depends on the IgG fraction and its capacity to deposit in 
glomeruli  
Sera collected from different SLE patients were tested in susceptible IIAIIIBγ-/-Mac-1-/- mice. 
Four out of six SLE sera induced nephritis, while sera from five healthy controls (normal serum), 
or heat aggregated human IgG (surrogate of ICs) failed to induce disease (Fig. 4A). Moreover, 
four out of five sera from SLE patients at an independent clinical center induced nephritis 
compared to normal controls (Sup. Fig.1D). Nephritis was observed with multiple SLE serum 
samples from the same patient when treatment and disease activity varied but circulating ICs 
remained elevated. IgG depletion of SLE serum “A” abrogated its nephritis-inducing capacity 
(Fig. 4B), which suggests that ICs in the sera are required for disease development (Fig. 2A). 
The sera that caused disease, henceforth referred to as “pathogenic sera” (e.g. SLE sera “A” and 
“E”), were associated with glomerular deposits of human IgG that exhibited a granular pattern 
characteristic of ICs (Fig. 4C). In contrast, no human IgG deposition was observed when “non-
pathogenic” sera were injected; these included SLE sera “D” and “F” and sera from healthy 
controls (Fig. 4C). All four human IgG isotypes, IgG 1-4 were observed in the glomeruli, 
predominantly as deposits in the mesangium (Fig. 4D). Specificity of the antibodies was 
confirmed by analyzing their reactivity against purified human IgG1-4 in western blots (data not 
shown). In the case of serum “A”, focal tubular basement membrane deposition of IgG was also 
detected (Fig. 4D), which is a pattern observed in human lupus nephritis. Sera pathogenicity (i.e. 
capacity of human ICs to deposit in glomeruli) did not correlate with the amount of ICs or IgG 
present in the sera (Sup. Table 1A), nor did it correlate with the patient type or lupus 
manifestations (Sup. Table 1B). 
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The susceptibility conferred by Mac-1 deficiency is not due to defects in IgG clearance  
Levels of circulating (Fig. 5A) and deposited human IgG-ICs (Fig. 5B) as well as glomerular 
complement C1q and C3 deposition (Fig. 5B) were comparable between hFcγR expressing mice 
that were Mac-1 sufficient (IIAIIIBγ-/-) or deficient (IIAIIIBγ-/-Mac-1-/-), as were peripheral 
blood neutrophil and leukocyte counts (Sup. Table 1C).  
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Passive transfer of human SLE serum induces arthritis in mice 
Notably, two of the “pathogenic” SLE sera, “A” (Figure 6) and “E” (data not shown) caused 
arthritis in mice that affected primarily small joints, namely the distal interphalangeal and was 
evident at day 4. Patient “A” had clinical manifestations of arthritis, and Patient “E” did not have 
arthritis, but presented with Raynaud syndrome. There was no correlation between human 
symptoms and arthritis development as some sera from patients that clinically presented with 
nephritis and arthritis did not induce arthritis in mice (data not shown). Moreover, unlike 
nephritis, development of arthritis was more variable with different sera samples. As occurred 
with the nephritis, only hFcγR expressing mice lacking Mac-1-/- developed arthritis (Fig. 6A). 
Histopathological analyses revealed intense joint inflammation with cellular infiltration 
associated with bone and cartilage destruction (Fig. 6B). Significant deposition of human IgG-IC 
within synovial blood vessels was observed in both disease-susceptible and non-susceptible mice 
(Fig. 6C). Neutrophils were abundant in the lesions (Fig. 6D) while macrophages and T cells 
were not detected (data not shown).  
Marked glomerular neutrophil infiltration is observed in susceptible mice while 
macrophages do not contribute to disease 
Susceptible mice (hFcγR+γ-/-Mac-1-/-) exhibited abundant glomerular neutrophil infiltration at 
day 10 that significantly exceeded that in non-susceptible mice (Fig. 7A). In contrast, a mild 
interstitial macrophage and T cell infiltration was observed in both groups of mice (Fig. 7A). 
Thus Mac-1 deficiency appears to selectively enable neutrophil accumulation. To distinguish if 
the Mac-1-expressing cell responsible for resistance to nephritis corresponded to circulating (i.e. 
monocytes or neutrophils) or resident cells, we generated bone marrow chimeras. Bone marrow  
22 
 
 
 
23 
 
from IIAγ-/- or IIAγ-/-Mac-1-/- mice was transferred into lethally irradiated γ-/-Mac-1-/- or γ-/- mice, 
respectively (i.e. IIAγ-/- → γ-/-Mac-1-/- and IIAγ-/-Mac-1-/- → γ-/-), and 3 months later SLE serum 
was administered. IIAγ-/-Mac-1-/- bone marrow provided susceptibility to nephritis when 
transferred into non-susceptible γ-/- mice suggesting that a lack of Mac-1 on hFcγRIIA expressing 
circulating cells allows the development of disease (Sup. Fig.  2A). Immunohistochemistry in 
tissue of γ-/-Mac1-/- recipients of IIAγ-/- bone marrow revealed Mac-1 positive macrophages in the 
renal interstitium following human SLE serum transfer, suggesting that SLE serum induces renal 
infiltration of blood monocytes and their subsequent differentiation into macrophages (Sup. Fig. 
2A). To determine if monocytes/macrophages contribute to renal injury, these populations were 
depleted prior to SLE serum transfer by administering clodronate liposomes, which are 
internalized by these cells and leads to their apoptosis (Sup. Fig. 2B). Macrophage-depleted IIAγ-
/-Mac-1-/- mice remained highly susceptible to nephritis (Fig. 7B) suggesting that macrophages 
do not significantly contribute to renal injury. Moreover, macrophage-depletion in disease non-
susceptible (IIAγ-/-) mice did not result in proteinuria (Fig. 7C) or glomerular neutrophil 
infiltration (data not shown) at day 10, suggesting that Mac-1 deficiency in 
monocytes/macrophages does not enable disease.  
Mac-1 deficiency modifies the response of neutrophils towards tissue deposited immune 
complexes in vivo  
Intravital microscopy experiments were performed by Kan Chen and Kevin Croce 
To elucidate the mechanism(s) by which Mac-1 regulates FcγRIIA-mediated neutrophil 
accumulation, we conducted intravital microscopy of the cremaster muscle that allows the real 
time visualization of neutrophil behavior within the vessel wall. The Reverse Passive Arthus  
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(RPA) reaction, induced by the intravenous administration of soluble BSA and an intrascrotal 
injection of anti-BSA results in IC deposition within and outside the cremasteric vessels (15,46). 
The RPA induces neutrophil rolling that is P- and E-selectin dependent (46), while the slowing 
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of the rolling velocity and adhesion is dependent on murine FcγRs (47) and FcγRIIA (15). 
Following induction of the RPA, neutrophils in the venules of IIAγ-/-Mac-1-/- mice rolled 
significantly slower than in IIAγ-/- mice (Fig. 8A). This was not a result of differences between 
the two groups in expression of LFA-1 on circulating neutrophils or neutrophils recruited to the 
cremaster (Sup. Fig. 2C). The slow rolling required FcγRIIA, as it was not observed in γ-/-Mac-1-
/-, and γ-/- mice (Fig. 8B). The downmodulatory effect of Mac-1 was selective for ICs as the 
rolling velocity induced by an intrascrotal injection of TNFα was actually increased in IIAγ-/-
Mac-1-/- mice compared to IIAγ-/- mice (data not shown) as previously described (48). In the 
RPA, the observed slower neutrophil rolling in IIAγ-/-Mac-1-/- mice was not associated with an 
increase in the number of adherent cells compared to IIAγ-/- mice (Fig. 8C). E-selectin mediated 
activation of LFA-1 has been shown to slow neutrophil rolling velocity, and in turn lead to 
efficient firm adhesion only in response to a local chemoattractant stimulus, Macrophage 
Inflammatory Protein-2 (MIP-2) (42). Accordingly, the local microinjection of MIP-2 favored 
adhesion of neutrophils in IIAγ-/-Mac-1-/- compared to IIAγ-/- animals subjected to the RPA (Fig. 
8D). IC induced slow rolling and MIP-2 induced neutrophil adhesion is likely LFA-1 dependent 
as these steps were markedly diminished in CD18 deficient mice (Fig. 8E, F). 
In summary, FcγRIIA-dependent slow rolling, which correlates with efficient leukocyte adhesion 
in response to MIP-2 is regulated by Mac-1, with a deficiency in this integrin resulting in a 
further decrease in rolling velocity and subsequent enhanced responsiveness of neutrophils to a 
local chemotactic stimulus. 
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IV. Discussion 
In this study, we show in a novel lupus model that IC deposition and organ damage are not 
inextricably linked but that additional genetic factors dictate the propensity for target organ 
damage. In particular, we demonstrate that the neutrophil response to deposited ICs and 
subsequent tissue injury, following human lupus sera transfer is modulated by a functional 
association between an integrin and an IgG receptor. The role of Mac-1 in attenuating FcγRIIA 
mediated neutrophil recruitment in the context of deposited ICs, is unanticipated from previous 
work that have established Mac-1 largely as a positive regulator of neutrophil influx and 
inflammation (31,49). Our data predict that the R77H Mac-1 variant, which leads to reduced 
binding to its ligands, may have functional consequences for SLE patients and offer a 
mechanism by which Mac-1 dysfunction may contribute to end organ injury in SLE.  
Disease susceptibility permitted by the absence of Mac-1 was not related to alterations in IC 
handling presumably by macrophages. Moreover, Mac-1 on macrophages and indeed 
macrophages themselves did not influence disease susceptibility. Thus this cell type, abundant in 
SLE lesions (50) is not essential for target organ injury in our model at least in the time frame of 
our experiments. Instead Mac-1 deficiency likely predisposes to disease development due to 
unrestrained FcγRIIA mediated neutrophil accumulation in the kidney. The reported physical 
interaction of Mac-1 with human FcγRs on the cell surface (51), and the sharing of intracellular 
ITAM-based signaling cascades by these two receptors (52) led us to the intriguing possibility 
that Mac-1 on neutrophils, in cis, modulates neutrophil FcγRIIA activity and function.  
FcγRIIA on neutrophils clearly has the capacity to induce tissue injury in vivo (15,16). However, 
in the context of ICs deposits in the kidney and joints, the regulation of FcγRIIA mediated 
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neutrophil recruitment appears to be a key step in conferring disease susceptibility. Recent work 
suggests that binding of FcγRIIA to ICs and function may be regulated. In vitro, the G-protein 
coupled receptor agonists C5a and fMLP enhances (16,53) while co-engagement of FcγRIIB 
inhibits (54) FcγRIIA function. How is FcγRIIA regulated by Mac-1? Clues were provided by 
intravital microscopy. Slowing of the velocity of rolling cells improves their efficiency of firm 
adhesion (48) and in the RPA, FcγRIIA plays an important role in mediating slow rolling and 
leukocyte arrest (15). Additionally, CD18 integrins are required as slow rolling and MIP-2 
mediated adhesion in the RPA is abrogated in CD18 deficient mice. We postulate that FcγRIIA 
promotes the activation of LFA-1. A deficiency in Mac-1 heightens FcγR activity towards ICs 
and subsequent LFA-1 activation that in turn leads to further deceleration of the rolling velocity 
and increased responsiveness to MIP-2. Mac-1 may be responsible for mitigating FcγRIIA 
mediated signaling or limiting FcγRIIA mobility or clustering, the molecular details of which 
require further investigation. Human FcγRIIA appears to functionally interact with murine Mac-
1 in cis suggesting that this interaction uses conserved features of human and mouse Mac-1. 
The observed decrease in neutrophil accumulation in Mac-1 deficient mice in other models of IC 
mediated disease including acute anti-GBM, thrombotic glomerulonephritis, and bullous 
pemphigoid (40,55,56), suggest differential roles for Mac-1 in distinct models of IC-based 
diseases. Complex biological circuits predict dual and sometimes opposing roles for the same 
receptor that is cell type and context dependent. For example, incomplete phosphorylation of the 
ITAM following engagement of B or T cell receptors by low affinity/valency ligands favors 
inhibitory over activating signaling by these immune receptors (57). Moreover, non-sustained 
FcαRI clustering markedly inhibits whereas sustained FcαRI aggregation promotes cell 
activation through differential recruitment of the tyrosine kinase Syk versus an inhibitory protein 
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phosphatase SHP-1 (58,59). We posit that Mac-1 relays similar context dependent inhibitory and 
activating signals, a hypothesis that is supported by the finding that although the R77H Mac-1 
polymorphism is a susceptibility factor for lupus (24) it does not predispose to rheumatoid 
arthritis (60). Interestingly, FcγRIIIB may also play context dependent roles in IC mediated 
inflammation. While low expression of FcγRIIIB is associated with SLE (61), high FcγRIIIB 
levels increase susceptibility to anti-neutrophil cytoplasmic antibody (ANCA)–associated 
systemic vasculitides, diseases associated with in situ rather than soluble ICs (62). This concept 
is recapitulated in our mouse models. Human SLE serum induced nephritis was reduced in mice 
expressing both human FcγRIIA and FcγRIIIB versus FcγRIIA alone, which contrasts with the 
greater proteinuria following anti-GBM nephritis in mice expressing both hFcγRs compared with 
mice expressing FcγRIIA alone (15).  
Our studies suggest that neutrophils are the primary cellular link between IgG and target organ 
damage in our model. Neutrophils are present in renal SLE lesions (63,64), precede macrophage 
infiltration (63), and are appreciated as a sign of disease severity (65). Importantly, recent studies 
identified a subset of neutrophils in SLE patients that synthesize type I IFNs, induce endothelial 
cell damage (66), release neutrophil extracellular traps (NETs) that are potentially autoantigenic, 
and drive IFNα production by dendritic cells (67,68). SLE sera transfer results in the 
development of lesions that recapitulate several features of lupus nephritis. The mice obviously 
lack the imbalances in the adaptive immune response and therefore chronicity of the disease. 
However like SLE patients, where development of lupus nephritis is not associated with 
autoantibodies of singular IgG specificity (68), a spectrum of IgG1-4 subtypes were found 
deposited in the glomeruli, with the capacity of SLE sera to induce proteinuria being directly 
correlated with their ability to deposit. Histological features similar to human disease include 
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mesangial hypercellularity and mesangial deposits (mainly IgG), C3 deposition, endocapillary 
and extracapillary proliferation (crescents) and neutrophils. The lack of the interstitial 
component, thickening of the membrane, or podocyte effacement is likely because the immune 
deregulation in SLE patients is much more profound than in our model.  Renal injury in our 
model is unlikely a consequence simply of an immune response against heterologous human IgG 
as normal human serum, some SLE patient serum and heat aggregated human IgG failed to 
induce nephritis and murine anti-human IgG antibody deposition in the glomeruli. 
Indiscriminate immunosuppression remains the prevailing therapy in SLE with significant 
toxicity, and the expectations from therapeutic targeting of the aberrant immune system have 
remained unfulfilled (29). Our data in a humanized mouse model indicate that deposition of 
circulating autoantibodies is not sufficient for target organ damage. Rather, regulation of 
neutrophil FcγRIIA by Mac-1 fundamentally influences IC-mediated end organ damage. 
Moreover, our humanized passive SLE sera transfer model will aid in delineating additional 
mechanisms specifically driving lupus induced tissue injury and serve as a preclinical platform to 
test new therapeutics targeted at preventing lupus end organ damage. 
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Chapter 3. Evaluation of the role of Mac-1 in autoimmune organ damage 
 
Evidence obtained in patients with SLE and their healthy relatives, as well as data from murine 
models of autoimmune disease, indicate that tolerance failure is not sufficient to generate end 
organ damage. This suggests that factors that regulate local inflammation and effector responses 
to products of the autoimmune response (i.e. deposited ICs) dictate susceptibility to end organ 
damage. Accordingly, we have shown that Mac-1 modulates the activation of neutrophils 
through FcγRIIA and only in its absence does ICs trigger a pathogenic response (26). To provide 
further evidence that Mac-1 exerts a protective role by limiting the activation of neutrophils in 
the context of autoimmune end organ damage, we tested the hypothesis that immune complex 
generation in a congenic Sle1b lupus prone mouse model characterized by high circulating ICs, 
will result in glomerulonephritis only when neutrophil FcγRIIA is expressed in the absence of 
Mac-1.   
In the current view of SLE pathogenesis, each element of the immune system contributes to the 
disease in a specific manner. This has been studied by Wakeland’s group in a spontaneous 
murine model of lupus (NZM2410 mice). Through genetic analyses, they have demonstrated that 
the development of autoimmune disease in NZM2410 mice is governed by three risk loci 
independent of the MHC (69). These loci (Sle1, Sle2, and Sle3) have been expressed 
independently in the C57BL/6 background and their contributions to disease have been studied. 
Mice carrying the Sle1 locus develop high titers of IgG anti-nuclear autoantibodies. However, 
their frequency of nephritis is low (less than 20% of mice develop glomerulonephritis at the age 
of 12 months) and its severity is minimal. In contrast, the Sle2 locus affects the behavior of B 
cells and induces elevated levels of polyreactive IgM. The Sle3 locus causes high titers of IgM 
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and IgG and severe nephritis (70). Within the Sle1 congenic interval, three sub-loci have been 
associated with loss of tolerance to chromatin:  Sle1a, Sle1b, and Sle1c. The effects of the Sle1b 
sub-locus are dominant, as the serological and cellular characteristics closely resemble those of 
mice that carry the complete Sle1 interval (71).  
In order to evaluate the hypothesis that Mac-1 has a role in the protection against end organ 
damage, we used the Sle1b mice as a model were the tolerance breach has occurred, but the 
autoimmune response has not resulted in organ inflammation and clinical manifestations. For 
this purpose we introgressed Sle1b into the Mac-1-/- mice in the presence or absence of human 
FcγRIIA. Mice were followed for one year (Fig. 9A) and evaluation of the development of 
glomerulonephritis was assessed by the presence of albuminuria. Histologic signs of active 
involvement of the glomeruli by lupus nephritis manifested by leukocyte neutrophilic infiltration 
(0-3), cellular proliferation (0-3), wire loop (0-3), and crescents formation (0-3) were assessed as 
previously described (38). A combined score was generated and mild and severe lupus nephritis 
activity was considered based on 1-4 and ≥5 of total scores, respectively.  
Significant levels of albuminuria were detected at 6 months of age in Sle1b mice that expressed 
FcγRIIA and lacked Mac-1-/- (Fig. 9B). The histological evaluation of the kidneys performed on 
samples from 12 month old mice, revealed that the presence of FcγRIIA in the Sle1b mice 
increased the susceptibility for development of glomerulonephritis (i.e. 20% of Sle1b mice 
developed mild glomerulonephritis whereas all Sle1bFcγRIIA mice succumbed to disease; 80% 
mild and 20% severe). Importantly, the absence of Mac-1 in Sle1bFcγRIIA mice markedly 
increased the severity of glomerulonephritis (i.e. all Sle1bFcγRIIA mice developed 
glomerulonephritis; 33% mild and 66% severe) (Fig. 9C). It is worth mentioning that two 
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specimens that expressed Mac-1 showed abundant ICs deposition (manifested by several wire 
loops), but no neutrophil infiltration.  
 
 
 
These results support a role for Mac-1 as a critical regulator of neutrophil responses to deposited 
ICs that leads to tissue damage.  We proposed that the absence of Mac-1 on neutrophils bearing 
FcγRIIA lowers their threshold of activation leading to tissue injury. However, there are 
alternative explanations for our findings. For example, we cannot rule out the possibility that 
Mac-1 deficiency on other cell types, such as B-cells, macrophages or NK cells indirectly 
influences neutrophil FcγRIIA function. The finding that the presence of FcγRIIA alone 
increases the risk for glomerulonephritis is interesting, because it may reveal the potency of the 
human FcγRIIA vs. the mouse activating FcγRs in SLE-IC-induced tissue damage.  However, we 
cannot rule out the possibility that it is due to an increase of the total FcγR pool (i.e. endogenous 
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murine FcγRs and FcγRIIA) and therefore potentially a greater neutrophil response to ICs. It is 
possible that the absence of Mac-1 promotes neutrophil accumulation indirectly. That is, kidney 
inflammation could further amplify the autoimmune response by increasing the availability of 
autoantigens, and their presentation in an inflammatory setting. Finally, it is possible that the 
human FcγRIIA in mice is more potent than the murine FcγRs because it does not engage the 
regulatory machinery that modulates murine FcγR activity. For example, human FcγRIIB 
downregulates FcγRIIA responses in macrophages, a process that may not happen with murine 
FcγRIIB. This is an unlikely explanation as neutrophils do not express FcγRIIB (72).  Further 
analyses (described in the next chapter) will be pursued to better delineate the mechanisms 
through which Mac-1 negatively regulates FcγRIIA dependent neutrophil activation and organ 
damage.   
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Chapter 4. Engagement of Mac-1 on neutrophils generates intracellular signals that can 
potentially modulate the activity of FcγRIIA 
 
 
I. Introduction 
Neutrophils are abundant, terminally differentiated cells that are rapidly recruited to sites of 
inflammation, where they efficiently engulf and eliminate pathogens through the production of 
reactive oxygen species (ROS) and the release of proteolytic enzymes. Once activated, 
neutrophils also produce chemokines and cytokines that amplify the intensity and the duration of 
the immune response. These mechanisms contribute to the efficient clearance of pathogens and 
shape the landscape for the ensuing adaptive immune response. However, in the context of sterile 
inflammation, such as in autoimmune diseases, the products released by neutrophils can promote 
significant tissue injury (64).  
In autoimmune conditions where high amounts of immune complexes exist (due to excessive 
production or deficient clearance), neutrophils are activated through surface receptors, such as 
Fcγ receptors (FcγR) and the complement receptor Mac-1. FcγRs are a heterogeneous group of 
molecules that bind the constant region of IgG. These molecules are expressed by many cell 
types including neutrophils, monocytes, natural killer cells, dendritic cells (DC), and basophils. 
Functionally, FcγR can be divided into activating and inhibitory receptors that transmit their 
signals via ITAM or ITIM, respectively. All murine activating FcγRs (FcγRI, FcγRII, FcγRIII, 
and FcγRIV) require the presence of the signaling γ-chain (which contains an ITAM) for their 
surface expression and signal transduction (73). Accordingly, mice deficient in γ-chain do not 
express any activating FcγR and are protected in several models of IC-mediated inflammation 
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(e.g. SLE-serum (26) and anti-GBM induced nephritis, RPA reaction (15), and  KBxN arthritis 
(16)). Human cells express three families of FcγR: FcγRI, FcγRII (FcγRIIA, FcγRIIB, FcγRIIC), 
and FcγRIII (FcγRIIIA and FcγRIIIB). They all possess extracellular Ig-like domains, but differ 
in their transmembrane and intracytoplasmic regions. FcγRIIA is a single polypeptide chain 
containing an activating motif (ITAM) in its cytoplasmic domain. This molecule, which has no 
murine homologue, preferentially binds IgG forming ICs (73). Due to the differences between 
human and mouse neutrophil FcγR repertoire, murine models have been inadequate to evaluate 
the physiological functions of the human neutrophil FcγR and their contribution to disease. 
Moreover, the specific role of neutrophil FcγRs in disease pathogenesis has been limited in 
mouse models generated with global deletions of activating receptors. This has limited our 
capacity to understand the role of specific human FcγRs in neutrophils under physiological or 
pathological conditions. This issue has been addressed by the generation of transgenic mice that 
express FcγRIIA selectively on neutrophils. By crossing these mice with γ-/- mice (that lack all 
murine activating FcγR) the role of FcγRIIA has been examined. Transgenic mice expressing 
human FcγRIIA on neutrophils significantly regain susceptibility to IC-mediated diseases, 
suggesting that FcγRIIA on neutrophils may serve as a primary link between ICs and tissue 
injury (15,16).  
Given its potent pro-inflammatory functions, FcγRIIA activity on neutrophils must be tightly 
regulated, yet the mechanisms for this remain largely undefined. The ITIM-bearing FcγRIIB has 
been described as a modulator of FcγR responses, through the action of the inositol 
polyphosphate 5-phosphatases SHIP-1, SHIP-2 and SHP1 (SH2-domain-containing protein 
tyrosine phosphatase-1). These molecules oppose the signaling pathways activated by FcγRIIA 
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by hydrolyzing phosphoinositide intermediates. In addition, SHIP activation (through 
phosphorylation) has been proposed to result from FcγRIIA activity, as a negative feedback 
mechanism (74). SHP-1 has also been found to associate with the ITAM of FcγRIIA and to 
dephosphorylate the p85 subunit of PI3K and Syk, downstream molecules activated by FcγRIIA 
(75).   We have demonstrated that the β2 integrin Mac-1, inhibits FcγRIIA-induced slow rolling 
of neutrophils over ICs and protects against the development of FcγRIIA-dependent 
glomerulonephritis, suggesting that Mac-1 is a regulator of FcγRIIA activity. Physical interaction 
between Mac-1 and FcγRIIA by fluorescent resonance energy transfer (FRET) and by 
coimmunoprecipitation has been described. This interaction has been found to be via the I-
domain (E252-R261) of Mac-1 (76) and has been mostly regarded as pro-inflammatory because it 
enhances Fc-dependent phagocytosis, antibody-dependent cell-mediated cytotoxicity, cytokine 
production (i.e. LTB4), and adhesion to ICs (76). However, it is becoming clear that Mac-1 can 
also exert negative functions over effector receptors (18,19,77).  
The overall aim of this section was to study the mechanism through which the FcγRIIA signaling 
cascade is modified by Mac-1 engagement. 
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II. Material and Methods 
Antibodies and Reagents 
The following Abs were used for Western blot analysis: rabbit anti-p-PLCγ, rabbit anti-p-Akt, 
rabbit anti-p-Pyk2, rabbit anti-p-ERK1/2, rabbit anti-p-PKCδ, rabbit anti-p-p40(phox) (Cell 
Signaling Technology); mouse anti-β-actin (Sigma). Anti-Rabbit IgG HRP-conjugated antibody 
was purchased from Cell Signaling and anti-mouse IgG HRP-conjugated antibody from Jackson 
ImmunoResearch.  
Goat anti-mouse IgG (Kirkegaard & Perry Laboratories) and mouse anti-FcgRIIA (StemCell, 
clone IV.3) antibodies were used to coat plates for crosslinking experiments. Immune complexes 
on a plate were formed using anti-BSA and BSA (Sigma).  Anti-CD32 FITC (BD bioscience) 
and anti-CD11b APC conjugated antibodies were used for flow cytometry analyses. Lyn 
phosphorylation was inhibited by preincubating the neutrophils with PP1 (Sigma, 10nM), before 
activation through FcγRIIA.  
Mice  
C57BL/6J mice expressing the FcγRIIA in a γ-chain deficient background (IIAγ-/-) (15) were 
breed with C57BL/6J PKCδ-/- mice, to obtain mice that express FcγRIIA in γ-chain and PKCδ 
deficient background (IIAγ-/- PKCδ-/-). Mice that express FcγRIIA in γ-chain and Mac-1 deficient 
background (IIAγ-/- Mac-1-/-) (26) were used as positive control.  Lyn-/- and WT control bone 
marrow neutrophils were obtained from Dr. Lowell’s laboratory (UCSF, CA). Mice were bred 
and maintained in a virus- and antibody-free facility. Experiments performed with these mice 
were approved by the Harvard Medical School Animal Care and Use Committee. 
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Cells isolation and crosslinking analyses 
Bone marrow neutrophils were isolated from femurs and tibias by washing out the bone marrow 
with ice-cold RPMI 2% FCS. Using a percoll based gradient, neutrophils were collected from the 
section obtained in the 65 and 75% percoll. Cells were used immediately after isolation.  
For crosslinking of FcγRIIA, plates were coated with a goat-anti-mouse antibody (5µg/mL) in 
carbonate-bicarbonate buffer overnight at 4oC. The wells were then coated with an anti-FcγRIIA 
antibody. Results were confirmed with coting of plates with BSA-antiBSA immune complexes 
as previously described (15).  BMN were placed in the plates, and were centrifuged for 1 min at 
500 rpm, to homogenize the starting point. The assays that followed were performed at 37oC.    
Western blots 
Bone marrow neutrophils were placed on a plate and incubated for the indicated times at 37oC. 
Cell were directly lysed in loading buffer containing 2β-mercapto-ethanol and boiled. Proteins 
were loaded in 4-20% SDS gels (BioRad) under reducing conditions and transferred to a 
nitrocellulose membrane. Protein containing membranes were probed with relevant primary 
antibodies, followed by HRP-conjugated antibodies, and were developed using ECL and femto 
(in particular when probed for phospho-PKCδ) (ThermoScientific).    
Spreading assay 
Cell crosslinking was induced over coated glass coverslips for 30min. Cells were washed 3 
times, and fixed with 4% paraformaldehyde for 10 min. After saponin permeabilization (0.1%, 
for 2 mins) the cells were stained with phalloidin (Invitrogen) and the coverslips were placed on 
slides in mounting media with DAPI.  
40 
 
ROS production 
Bone marrow neutrophils were incubated in plates pre-coated with crosslinking-antibodies, in 
HBSS medium containing homovanillic acid and peroxidase IV (Sigma). After 60min, ROS 
production was measured in a fluorescence plate reader (Molecular Devices). ROS production 
was inhibited by pretreatment of the cells with DPI (10µm; Sigma).  
Induction of nephritis using SLE-serum and evaluation of albuminuria 
Induction of nephritis was performed as previously reported (26). Briefly, mice were immunized 
with complete Freund’s adjuvant with hIgG intradermically. Three days after, two intravenous 
injections of 200µL of serum were performed (on day 0 and 2).  Urine was collected on day 0, 7 
and 14 and analyzed for the presence of albumin by ELISA (Bethyl Labs).   
HL-60 culture and transduction 
HL-60 cells were cultured in RPMI 1640 supplemented with 10% of heat-inactivated FCS, 2mM 
of L-glutamine and penicillin/streptomycin (0.1 mg/ml). Cell differentiation was achieved by 
adding 1.25% DMSO to the culture media for 7 days.  For virus preparation, 293T cells (clone 
17, from ATCC) were transfected with the lentiviral construct containing the scrambled or 
hCD11b-specific shRNA sequence (MISSION shRNA lentivirus, Sigma-Aldrich) in addition to 
the packaging plasmids psPAX2 and pMD2.G (Addgene) using Lipofectamin (Invitrogen). 24hrs 
after transfection the cells were washed. Media was collected at 48 and 72hrs, and HL60 cells 
were infected using the supernatant of the transfected cells (previously clean by a 0.25µm filter). 
A stable cell line was generated by selection of shRNA expressing cells with puromycine (1 
µg/mL).  
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III. Results 
Clustering of FcγRIIA by immune complexes initiates a cascade of signaling events. Activation 
of the Src family of tyrosine kinases (e.g. Hck, and Lyn (78,79)) phosphorylates the FcγRIIA 
ITAM that in turn serves as a docking site for SH-2 domain containing cytosolic enzymes and 
adapters such as Syk and the p85 subunit of PI3K. Recruitment of Syk, via its SH2 domains, to 
the dual phosphorylated tyrosine residues in the ITAM motif, results in its activation. Activation 
of Syk leads to its association with, and phosphorylation of, many downstream substrates 
including the adaptor protein SLP76, the guanine exchange factors for Rac GTPases, Vav and 
PLCγ and p85 of PI3K. p85 brings PI3K in proximity to its substrates at the cell membrane, 
which results in the formation of phosphatydilinositol-3,4,5-triphosphate (PIP3). PIP3 creates a 
docking site for pleckstrin homology (PH)-domain containing enzymes such as Bruton’s tyrosine 
kinase (BTK) and phospholipase Cγ (PLCγ) (80). Together, these receptor proximal complexes 
trigger an increase in downstream processes including an increase in calcium levels, PKC 
activation (73), and Pyk2 dependent cytoskeletal re-arrangements.  
FcγRIIA crosslinking-induced phosphorylation of PKCδ and Pyk2 depends on Mac-1  
Neutrophils from mice that transgenically express FcγRIIA, (without other murine activating 
FcγRs receptors; γ-/-), in the absence or presence of Mac-1 were used to evaluate how the 
signaling cascade induced by FcγRIIA crosslinking on neutrophils was modified by Mac-1. 
Expression of FcγRIIA was comparable between these cells (Fig. 10A).   
Neutrophil spreading over ICs has been shown to be dependent on Mac-1, suggesting that 
FcγRIIA crosslinking induces inside-out activation of Mac-1 (40) and signaling through Mac-1 
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(Fig. 10B).  In order to engage Mac-1 during signaling of FcγRIIA, crosslinking was induced on 
a plate bound assay. Neutrophils were added to ICs, and lysates were collected at the indicated 
time points. 
Phosphorylation of several known FcγRIIA- and Mac-1-induced proteins was evaluated. 
Interestingly, PKCδ, a novel PKC that has been shown to have negative regulatory properties  
towards ITAM-bearing receptors (i.e. FcεR on mast cells (81), GPVI on platelets (82), and the B 
cell antigen receptor (BCR) (83)) was shown not to be phosphorylated in the absence of Mac-1 
(Fig 10C). Clustering of Mac-1 has been shown to induce PKCδ translocation to the membrane 
and its activation by phosphorylation by the Src kinases, Hck and Lyn (84). The negative 
regulatory effect of PKCδ has been proposed to be by activation of the 5-phosphatase SHIP-1 
that interferes with effector signaling pathways by hydrolyzing PIP3 to PIP2. In the context of 
FcεR and GPVI, Lyn-dependent phosphorylation of PKCδ was shown to be necessary for its 
association with SHIP-1 (81,82).  
Phosphorylation of the proline-rich tyrosine kinase 2 (Pyk2) was also induced upon FcγRIIA 
crosslinking in a Mac-1-dependent manner (Fig. 10C). It has previously been shown that Pyk2 
activation requires engagement of the β2 integrins, LFA-1 and Mac-1 (49,85). Activation of 
Pyk2 by Src kinases leads to actin reorganization and activation of downstream MAPK. In 
macrophages, Pyk2 has been shown to negatively regulate TLR4- (18,86) and Dectin-1- (87) 
induced signaling and IL-10 production (18,86). The formation of the SHP-1-Pyk2-Src proteins 
complex was shown to be important for negative regulatory properties of Pyk2 (86).  FcγRIIA-
induced activation of PLCγ, AKT, p40phox, and Erk1/2 were not affected by the absence of 
Mac-1 (Fig. 10C). 
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Potential negative role for FcγR-mediated ROS generation in autocrine, down-regulation of 
FcγR signaling  
Neutrophil adhesion enhances ROS production likely through integrin signaling (88).  Using the 
plate bound FcγRIIA crosslinking assay, Mac-1-deficient cells showed a defect in cell spreading 
and accordingly, impaired ROS production (Fig. 11A). Similarly, PKCδ -/- neutrophils exhibited 
a reduction in FcγR generation of ROS in the plate bound crosslinking assay (Fig. 11B). 
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Although it is clear that excessive ROS production may be deleterious, it may also serve as a 
second messenger. For example, ROS has been shown to activate PKCδ (89). Furthermore, 
activation of SHIP by NADPH oxidase-stimulated Lyn has also been reported (90). Thus, we 
hypothesized that Mac-1/PKCδ-dependent ROS generation negatively regulates FcγR activity 
through activation of Lyn. In order to study the contribution of ROS in FcγRIIA signaling, a 
specific NADPH oxidase pharmacological inhibitor (DPI) was used. As expected, ROS 
production was completely inhibited, as well as cell spreading (91) (Fig. 11C).  Interestingly, 
phosphorylation of PKCδ and Pyk2 were also inhibited (Fig. 11D). Phosphorylation of other 
molecules like p40phox, were not affected, recapitulating the phenotype induced by Mac-1 
deficiency.   
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Role of Lyn in Pyk2 and PKCδ activation in the context of FcγRIIA crosslinking 
PKCδ and Pyk2 have been shown to be downstream of Lyn, and their activation depends on 
ROS after FcγRIIA crosslinking. Thus, we hypothesized that, upon FcγRIIA engagement, 
NADPH-stimulated Lyn will be necessary for PKCδ and Pyk2 phosphorylation. To test this 
hypothesis, bone marrow neutrophils from Lyn-/- mice were used. Murine FcγR were crosslinked 
in a plate using ICs, and cell lysates were evaluated by Western blot. Phosphorylation of PKCδ 
and Pyk2 was not only present, but enhanced in the absence of Lyn (Fig. 12A). To rule out the 
possibility that FcγRIIA was triggering different regulatory responses than its murine FcγR 
counterparts, a pharmacological inhibitor or Src kinases (PP1) was tested in neutrophils from 
FcγRIIAγ-/- mice. Again, of PKCδ and Pyk2 was enhanced when cells were treated with PP1 
(Fig. 12B).  
 
IIAγ-/-PKCδ-/- mice are not susceptible to SLE-serum induced nephritis  
To test the hypothesis that the regulatory activity of Mac-1 on FcγRIIA requires PKCδ, we 
generated mice that express FcγRIIA (in the absence of other murine FcγR), and additionally 
lack PKCδ (FcγRIIAγ-/-PKCδ-/-), and injected them with pathogenic SLE patient serum (26). 
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Mice that express the FcγRIIA, with or without Mac-1 were used as negative and positive 
controls, respectively. Albumin in the urine was evaluated as a read-out of glomerular damage.  
FcγRIIAγ-/-PKCδ-/- mice were resistant to developing nephritis by the SLE serum (Fig. 13). 
These results suggest that the regulatory properties that Mac-1 exerts over FcγRIIA activity, are 
not critically dependent on PKCδ. 
 
Strategy for an unbiased evaluation of Mac-1 modulation of FcγRIIA signaling upon 
crosslinking.  
In order to identify signaling molecules or pathways modified by Mac-1 that may be potentially 
important in regulating FcγRIIA activity, we are planning to perform an unbiased evaluation of 
FcγRIIA signaling by SILAC (stable isotope labeling with amino acids in cell culture). To 
perform this experiment, cells have to be propagated in culture for long periods of time to 
incorporate the labeled amino acids, Therefore, primary neutrophils are not suitable cells for this 
purpose. Thus, we turned to HL-60 cells, which are human promyelocytic leukemia cells that can 
be differentiated into a neutrophil-like cells using DMSO or DMEF in the medium culture. I 
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have generated two stable HL-60 cell lines, that express scrambled or hCD11b shRNAs (Fig. 
14A). When the expression of Mac-1 was knocked-down, cells did not spread over ICs, as we 
described for Mac-1-/- murine neutrophils (Fig. 14B). These cells will serve as a great tool to 
study how Mac-1 may modify signaling downstream of FcγRIIA.  
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IV. Discussion 
FcγRIIA crosslinking on a plate bound assay induces Mac-1-dependent spreading and signaling 
(phosphorylation of PKCδ and Pyk2), that results in enhanced ROS production. ROS may be 
part of a negative feedback loop that downregulates FcγRIIA signaling. Because Mac-1 enhances 
ROS, its activation could contribute to FcγRIIA inhibition by enhancing an ROS-dependent 
negative feedback loop. Accordingly, pharmacological inhibition of ROS phenocopies Mac-1 
deficiency.  
It is challenging to demonstrate this hypothesis, because we currently lack a functional read-out 
of Mac-1 dependent negative regulation of FcγRIIA. As discussed in the Introduction, Mac-1 can 
couple with FcγRs to enhance neutrophil functions in vitro and in vivo (40), while in vivo, we 
have a clear demonstration that Mac-1 can be inhibitory in a pathway that we propose is linked 
to FcγRIIA downregulation. The identification of a way to elicit Mac-1 inhibitory functions in 
vitro, by differential engagement of Mac-1 is being pursued to address this problem.  
Interestingly, the downregulation of PKCδ by the absence of Mac-1 seemed to be specific for the 
context of FcγRIIA. When crosslinking of murine FcγR was performed, the absence of Mac-1 
did not modify the PKCδ. We believe that it is possible that FcγRIIA induces different signals 
compared to murine FcγRs, and uniquely crosstalk with Mac-1. This serves as a further impetus 
to delineate the Mac-1 dependent inhibitory pathways regulating human FcγRIIA. The 
evaluation of how Mac-1 regulates FcγRIIA signaling in a large unbiased screen using the 
human cell line (i.e.HL-60 cells) will provide valuable data in this respect.  
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The observed resistance to the SLE-serum induced nephritis of the FcγRIIA mice lacking PKCδ-
/- mice suggests either that PKCδ does not significantly contribute to the generation of negative 
signals affecting FcγRIIA function or that PKCδ deficiency on other cell types prevents the 
development of glomerulonephritis, independent of its direct role on FcγRs. The latter, can be 
evaluated using bone marrow chimeras of FcγRIIAγ-/-PKCδ-/- cells, into not genetically modified 
host, to analyze their susceptibility to SLE-serum induced nephritis.  
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Chapter 5. A lupus-associated variant of Mac-1 exhibits defects in integrin allostery and 
force induced integrin interactions with ligand.  
 
I. Introduction 
Leukocytes rapidly adhere upon changes in the affinity and avidity of their integrins for ligands 
presented by activated endothelium, platelets and microbes. Adhesion via the leukocyte CD18 
integrin, composed of a α (CD11) and β (CD18) subunit, promotes leukocyte recruitment and 
the elimination of microbes. Overall, the integrin is in equilibrium between low, intermediate and 
high affinity conformations with cell activation, ligand binding, and the cytoskeleton regulating 
the equilibrium between these states. (92). Mechanical forces also contribute to changes in 
integrin binding affinity probably by inducing conformational changes. Application of force 
prolongs the lifetime of the interaction between integrins such as α5β1 (93) and the β2 integrin 
LFA-1 (94) with their respective ligands (95,96) in a process referred to as “catch-bonds”. Such 
tensile forces allow integrins on circulating leukocytes to rapidly develop adhesive interactions 
with the vessel wall (97,98). During an immune response, β2 integrins may also experience force 
upon binding microbes or forming an immunological synapse with antigen presenting cells (99). 
Although there is clear physiological evidence for the importance of CD18 integrins and 
associated signaling proteins in immune responses both in humans and mouse models, there is no 
evidence to date that alterations in integrin allostery or catch bonds have pathological 
consequences. 
Genome wide association studies have identified a variant of the ITGAM gene, which encodes 
the α chain (CD11b) of the β2 integrin Mac-1 (macrophage-1 antigen complex; CD11b/CD18) 
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as a risk factor for systemic lupus erythematosus (SLE) (23,24), a multi-organ autoimmune 
disease (2). After the HLA, ITGAM is the second strongest locus associated with risk for SLE 
(24). The risk effect has been mapped to the single nucleotide polymorphism (SNP) rs1143679 
that results in the substitution of an Arginine for a Histidine in the position 77 (R77H) of CD11b 
(23,24). The strong association of the rs1143679 SNP with SLE has been confirmed in several 
populations (i.e. African, European and Hispanic, but was not associated in Korean and Japanese 
populations) by a meta-analysis that includes independent data sets with an overall odds ratio of 
1.83 (100).  Studies assessing the effect of the R77H variant in many cell types have concluded 
that compromised R77H ligand binding capacity contributes to SLE pathogenesis (25,77,101-
104). Yet, the molecular mechanism for how this variant may affect ligand binding is unclear, as 
it is not located in the ligand binding I domain.  
Mac-1 is expressed on myeloid cells with particularly high levels on neutrophils, and on some 
lymphocyte subsets, including NK and B cells. It has several ligands including complement 
iC3b, ICAM-1 and fibrinogen and promotes leukocyte recruitment and phagocytic uptake and 
destruction of targets (31). However, negative regulatory functions for Mac-1 have also been 
described. It can inhibit signaling through the B cell receptor (BCR), toll-like receptors (TLR), 
and type I interferon receptor (18,19,77). Moreover, recent work by our group demonstrated that 
in a model of lupus, Mac-1 protects against the development of glomerulonephritis induced by 
IgG-immune complexes by potentially negatively regulating the human IgG receptor, FcγRIIA 
(26).  
Structurally, the α and β subunits of integrins consist of N-terminal domains that form the 
integrin head, which connect to upper and lower legs, transmembrane domains, and short C-
terminal cytoplasmic tails. Overall, the integrin is in dynamic equilibrium between three states: a 
52 
 
bent closed headpiece conformation that is low affinity, an extended-closed conformation also 
with low affinity, and an extended-open headpiece conformation (99). Stimulation of cells with 
chemokines or divalent cations places the integrin in an intermediate affinity, which is driven to 
high affinity by ligand binding. The main ligand binding I-domain (headpiece) is inserted in the 
α-subunit β-propeller domain near its interface with the β2 subunit βI domain (105,106). The αI 
and βI domains are structurally homologous and ligand binding depends on the presence of 
divalent cations (Mg2+ or Mn2+) that bind to a Metal Ion-Dependent Adhesion Site (MIDAS) 
within both domains (107). The metal ion in the αI domain MIDAS coordinates an invariant Glu 
or Asp residue shared by all integrin ligands (108). Allostery is relayed by the interaction of the 
internal ligand formed by the α7 helix of the I-domain making contact with the MIDAS of the β 
subunit I-like domain. The pistoning of the α7 helix also contributes to the formation of catch 
bonds since an antagonistic molecule of the internal ligand site in the βI domain (XVA143) 
inhibits this process (94). Upon head piece opening, reshaping of the βI domain MIDAS, which 
is at the interface with the α subunit β-propeller domain is transmitted by the βI domain α7 helix 
downward shift to the interface with the hybrid domain causing the hybrid domain to swing out 
and full extension of the integrin. Bidirectional allosteric changes are required for productive 
ligand binding. In α I-less domain integrins (i.e. α3-α9 and αIIb), ligand binding occurs in the 
interphase between the α subunit β-propeller and the β subunit I-like domain (107). However, in 
α I-domain containing integrins it is unclear how the β-propeller domain, in which the SLE-
associated variant R77H resides, influences affinity.  
Here, we provide evidence that R77H substitution impairs the ligand binding capacity of Mac-1 
under shear flow by changing the equilibrium between the bent-closed and extended-open state 
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of the integrin and identify a novel role for R77 and the β-propeller domain in which it resides, 
in establishing force-induced catch bonds. Results from mutants introduced into the R77H and 
activating antibodies indicate that R77H prevents the transmission of bidirectional allosteric 
signals to the αI domain required for affinity and catch bond formation.  
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II. Materials and Methods  
Reagents and Antibodies 
Human IgM (Jackson ImmunoResearch), Protein A (Pierce Thermo Scientific), Human ICAM-
1Fc (R&D) and fMLP (Sigma-Aldrich) were purchased. Serum used as a source of iC3b was 
obtained from healthy volunteers. Blood was drawn and handled according to protocols for 
protection of human subjects approved by the Brigham and Women's Hospital Institutional 
Review Board, and all volunteer subjects gave written informed consent. CBRM1/29, 
CBRM1/32, CBRM1/20, CBRN1/6, CBRN 3/4, CBRLFA1/2 and CBRLFA1/7 were a gift from 
T. Springer (Harvard University, Boston MA) and were used as previously described (106,109). 
Anti-hCD11b activated (CBRM1/5), anti-hCD11b clone ICRF44, anti-hCD3, anti-hCD14, anti-
hCD32, anti-hCD16, anti-hCD11a, anti-hCD62L and goat anti-mouse IgG conjugated antibodies 
were purchased from BioLegend, and the anti-hCD18 (monoclonal antibody 24, m24) antibody 
from Abcam. Leukadherin-1 was purchased from Calbiochem (EMD Millipore).  
Lentiviral constructs 
The R77H mutation was introduced into the human CD11b using standard PCR approaches. 
cDNA constructs for CD18 L132A and V124A were a gift from T. Springer. cDNAs of CD11bWT and 
R77H , were cloned in the lentiviral plasmid pWPI (modified from the Addgene, plasmid #12254, 
from Didier Trono laboratory, by removing the EGFP cassette), whereas the cDNA for 
CD18WT/L132A and V124A, were cloned in the pWPI containing an EMCV IRES-EGFP cassette 
(Addgene plasmid #12254). GFFKR mutants (CD11bWT/GFFKR and CD11bR77H/GFFKR) were 
generating by including a stop codon before the GFFKR sequence, by standard PCR. 293T cells 
(clone 17, from ATCC) were transfected with the lentiviral construct (pWPI) in addition to the 
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packaging plasmids psPAX2 and pMD2.G (Addgene, plasmids #12260 and #12259 from the 
laboratory of Didier Trono) using Lipofectamin (Invitrogen). 24hrs after transfection the cells 
were washed. Media was collected at 48 and 72hrs, and K562 cells were infected with the 
supernatant of the transfected cells that had been passed through a 0.25µm filter. 
 
Cells  
K562 cells, which lack endogenous CD11b and CD18 expression, were transduced with 
lentiviruses. Single cell sorting was performed for positive expressing cells. Multiple clones 
expressing similar surface levels of CD11b were used in functional assays. Clones were cultured 
in RPMI 1640 supplemented with 10% of heat-inactivated FCS, 2mM of L-glutamine and 
penicillin/streptomycin (0.1 mg/ml) (Lonza). Genotyped human blood samples used in these 
studies were provided by the Genotype and Phenotype Registry, a service of the Tissue Donation 
Program at The Feinstein Institute for Medical Research, Manhasset, New York, USA. Samples 
from non- or variant (R77H)-carrying donors contained similar numbers of peripheral blood 
neutrophils. To evaluate the role of the β-propeller using antibodies, blood from non-genotyped 
healthy volunteers was used following the Human Use Committee Board of Brigham and 
Women’s Hospital guidelines. Neutrophil isolation from blood samples was performed as 
previously described (110).  
Static and shear flow adhesion assays  
Ligand coating of surfaces: iC3b coating was performed on 96 well opaque bottom plates 
(Costar) or glass coverslips. Human IgM (10µg/mL) diluted in carbonate-bicarbonate buffer (pH 
9.4) was incubated overnight at 4oC. Fresh serum was diluted 1:1 with PBS (Ca2+ and Mg2+) and 
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incubated at 37oC for 2hrs (heat inactivated serum was used as control). Blocking of unspecific 
binding to the surface was achieved by incubating with 1% PVP (Sigma) for 1hr at 37oC. ICAM-
1 coating on glass coverslips was as follows. Coverslips were incubate with Protein A (1µg/mL, 
used to orient the ICAM-1Fc molecules), for 1hr at 37oC, followed by ICAM-1 (10µg/mL) 
overnight at 4oC. Blocking of unspecific binding to the surface was achieved by incubating with 
2% BSA (Sigma-Aldrich) and 0.5%PVP for 1hr at 37oC. 
Integrin Activation: For integrin activation with Mg/EGTA, K652 cells were washed using 
Hanks balanced salt solution without Ca2+ and Mg2+ (HBSS-, Lonza) with 5mM EDTA, washed 
again using HBSS to remove EDTA and resuspended in HBSS containing Mg2+ and EGTA 
(2mM of each, Mg2+/EGTA). For Mn2+ induced activation, K562 cells were washed in Hepes 
buffer (20mM Hepes, 150mM NaCl, and 2mg/mL Glu) containing 2mM EGTA and 0.5mM 
MnCl2, and resuspended in Hepes buffer with 1mM MnCl2. Human neutrophils were activated 
with 500nM fMLP in PBS plus 2mM Ca2+ and Mg2+.  
Static adhesion assays: Cells were labelled with CFSE (Molecular Probes, Invitrogen), as 
recommended by manufacturer, and 25,000 cells were placed on ligand-coated wells of 96 well 
plates in the presence of the activation stimulus. The initial fluorescence intensity was measured 
by a spectrophotometer (Molecular devices). Cells were incubated for 30min at 37oC, and 
washed 4 times with warm buffer. Fluorescence intensity of the remaining cells was measured 
and the percentage of adhered cells was calculated. Static adhesion assays were also performed 
over glass coverslips used in the flow shear experiments, to rule out that differences in results 
between the static and flow assays was due to the ligand coating surface (i.e. glass versus tissue 
culture plastic). For these experiments, manual count of adherent cells in 4 different high power 
fields was performed, and the percentage of cells that adhered relative to CD11bWT treated with 
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Mn2+ was graphed. For blocking experiments using the anti-β-propeller antibodies, the percent 
inhibition relative to CBRLFA1/7 (antibody control) was calculated.  
Shear flow adhesion assay: Cells were perfused through a flow chamber at 1 dynes/cm2 for a 
min. Shear flow was then decreased to 0.38 dynes/cm2, and the number of cells accumulating in 
four different fields was counted every 2 minutes for the indicated time in minutes. Live-cell 
imaging of cell adhesion was recorded by a video camera coupled to a Nikon TE2000 inverted 
microscope equipped with a 20×0.75 NA phase contrast objective and VideoLab software 
(Mitov). 
Biomembrane force probe assays 
RBCs, platelets and beads preparation: Human red blood cells (RBCs) were isolated from whole 
blood of healthy volunteers by finger prick according to protocols approved by the Institutional 
Review Board of Georgia Institute of Technology. Freshly isolated human RBCs were firstly 
biotinylated by covalently linking with biotin-PEG3500-SGA (JenKem USA) for 30 minutes 
incubation at room temperature (94). Biotinylated RBCs were then incubated with nystatin 
(Sigma-Aldrich) in N2 buffer (265.2 mM KCl, 38.8 mM NaCl, 0.94 mM KH2PO4, 4.74 mM 
Na2HPO4, 27 mM sucrose; pH 7.2, 588 mOsm) for 30 minutes in 0oC. Nystatin-loaded 
biotinylated RBCs were washed twice with the N2 buffer and re-suspended in the N2 buffer for 
the BFP experiments.  
To obtain ICAM-1/streptavidin (SA) coated glass beads, borosilicate glass beads (Duke 
Scientific) were firstly covalently coupled with mercapto-propyl-trimethoxy silane (United 
Chemical Technologies). Meanwhile, ICAM-1 was covalently linked with NHS-PEG-MAL 
(JenKem USA) by incubation in carbonate/bicarbonate buffer (pH 8.5) for half an hour, and then 
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the complex together with streptavidin-maleimide (Sigma-Aldrich) was covalently linked to the 
glass beads in phosphate buffer (pH 6.8) for overnight incubation at room temperature and 
finally re-suspended in phosphate buffer plus 0.5% BSA. 
Measurement of molecular densities on the surfaces of BFP beads: To measure the Mac-1 
density, K562 cells were first incubated with a PE-conjugated anti-hCD11b antibody (ICRF44, 
BioLegend) at 10μg/ml in the D-PBS (0.493mM MgCl2, 1.47mM KH2PO4, 137.9mM NaCl, 
8.06mM Na2HPO4•7H2O, 0.884mM CaCl2, 2.68mM KCl, pH 7.4) at room temperature for 30 
minutes and then washed for 3 times in the D-PBS. To measure the surface ICAM-1 density, 
ICAM-1/streptavidin (SA) beads were first incubated with a PE-conjugated anti-ICAM-1 
monoclonal antibody (HA58, eBioscience) at 10 μg/ml in the phosphate buffer at room 
temperature for 30 minutes and then washed for 3 times in the phosphate buffer. Then 
fluorescent intensities of K562 cells or beads were measured by a BD LSR flow cytometer (BD 
Biosciences). The intensity results were compared to standard calibration beads (BD Quantibrite 
PE Beads, BD) to determine site densities of Mac-1 or ICAM-1 on K562 cells and beads, 
respectively (by dividing total number of molecules per cell or bead to the cell or bead surface 
area. The cell or bead surface area was calculated from the radii measured with a customized 
LabView (National Instrument) program (averagely 7.28μm for a K562 cell and 1μm for a bead). 
Biomembrane Force Probe (BFP) apparatus: The principles and technical details of BFP have 
been elaborated in previous papers (111,112). In brief, a streptavidinylated glass bead is glued to 
the apex of a biotinylated RBC, which is aspirated by a micropipette to form an ultra-sensitive 
force probe (Fig. 3A). The bead was coated with ICAM-1, which acts as the ligand for Mac-1 
(Fig. 3B). A K562 cell that was transfected to express Mac-1 is aspirated by an opposing 
micropipette, which is driven by a piezoelectric translator (Physical Instrument) with sub-
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nanometer precision via a capacitive sensor feedback control (Fig. 3A). The probe bead and the 
target cell are aligned in a cell chamber filled with the L15 chamber media (L15 with 1% BSA, 
5mM HEPES, 2mM Mg2+ and 2mM EGTA) and observed under an inverted microscope (Nikon 
TiE, Nikon) through two cameras. One camera (Prosilica) captured real-time images (Fig. 3A) at 
a video rate (30 frames per second, fps), while the other (Prosilica) does at a higher speed (1,600 
fps) when the images were limited to 100 pixel by 30 pixel rectangular region of interest across 
the contact interface between the bead and the RBC. A custom image analysis LabView 
(National Instrument) program tracked the bead position precisely in real-time (113). The 
binding kinetics measurements were described in following sections of lifetime assay, thermal 
fluctuation assay and adhesion frequency assay. 
The BFP spring constant k was determined from the suction pressure inside the probe pipette that 
holds the probe bead and the radius of the probe pipette, the diameter of the spherical portion of 
the RBC that is outside of the probe pipette, and the contact area between the probe and the RBC 
(111,112). It was set as 0.3pN/nm in the force-clamping assay for 10pN and higher clamping 
forces, and 0.25pN/nm for clamping forces lower than 10pN. 
Force-clamping assay: To measure bond lifetimes under a certain force, we used the force-
clamping assay which has been described previously (114). Generally, in the force-clamping 
assay, the K562 cell was driven repeatedly to approach and contact the probe bead with a 20-pN 
impingement force for 2s to allow a receptor-ligand bond to form. The target pipette was then 
retracted at a speed of 3μm/s. In the case that a binding event survived the retraction phase, the 
target pipette would be held at a desired clamping force to wait for the bond to dissociate, and 
then returned to the original position to start the next cycle (Fig. 3C). Lifetime was determined as 
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the time length from the instant when the force reached the desired level to the instant of bond 
dissociation.  
Thermal fluctuation assay: Thermal fluctuation assay is a BFP experimental mode that allows 
for lifetime measurements under zero-force (94,111). After touching the bead for a certain 
contact time, the K562 cell was retracted to the zero-force position and kept in contact with the 
bead via thermal motions without either compression or tension. Bond association/dissociation 
under zero-force was manifested as a sudden drop/increase in the thermal fluctuations of the 
bead, which is quantified by the average standard deviation of a sliding interval of 70 points of 
the bead’s position over time, σ.  
Adhesion frequency assay: Adhesion frequency assay uses a BFP experimental mode named 
force-rupture assay to measure the two-dimensional (2D) kinetics of the bonding between a 
receptor and a ligand by measuring the adhesion frequency. To detect an adhesion, the K562 cell 
was driven to approach and contact the probe bead at a given contact duration (tc) and retract, 
and an adhesion was signified by a tensile force signal caused by the retraction. This approach-
contact-retraction cycle was repeated 50 times for at least 3 cell-bead pairs at each tc (0.1, 0.2, 
0.5, 1, 2, 5 seconds). The probability of bond formation is summarized as an adhesion frequency, 
Pa, under each tc. 2D effective affinity (AcKa) and off-rate (koff) were derived by fitting the 
following Equation to Pa data at various tc (115),  
𝑃𝑎 = 1 − exp �−𝑚𝑟𝑚𝑙𝐴𝑐𝐾𝑎�1 − 𝑒𝑥𝑝�−𝑘𝑜𝑓𝑓𝑡𝑐���    (1) 
where mr and ml are the respective surface densities of Mac-1 and ICAM-1 measured by flow 
cytometry. The effective on-rate (Ackon) was then calculated as Ackon= AcKa·koff. 
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Lifetime analysis: We chose six forces, 5pN, 10pN, 15pN, 25pN, 30pN, 35pN to conduct force 
clamping experiments. According to the chosen clamping force, lifetimes were categorized into 
bins that cover successive force ranges, each of which has an approximate width of 5pN. The 
average lifetime in each bin was collected to plot the lifetime curve as a function of clamping 
force. 
Spring constant analysis: The spring constant of the integrin-ligand complex was analyzed based 
on the results of BFP force-rupture assay and force-clamping assay (116,117). During the 
retraction phase in each cycle, the slope of the force versus displacement curve reflected the 
spring constant of the system, including the cell and the molecular complex that were serially 
linked, while the stiffness of the bead and micropipettes are large enough to be neglected in 
contributing to the spring constant of the system. Thus, the reciprocal of the system spring 
constant, 1/ksys, equals the sum of the reciprocals of the cellular and molecular spring constants, 
1/kcell + 1/kmol. A reasonable assumption supported by previous calibrations (116) is that the 
molecular complex can resist tension but not compression, while the cell spring constant is the 
same regardless of tension or compression. Thus kcell and ksys were estimated from the respective 
slopes of the red and purple dashed lines, which are linear fits to the compression and tension 
segments, respectively, of the retraction phase in the force versus displacement curve (Fig. 3A). 
The molecular spring constant of the integrin-ligand complex was calculated by kmol = 1/(1/ksys-
1/kcell).  
The distribution of the spring constant values under each experimental condition is then fitted by 
a two-summit Gaussian distribution: 
p=A1*exp{-0.5*[(kx- kmol1)/D1]2}+A2*exp{-0.5*[(kx- kmol2)/D2] 2}        (2) 
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in which A1 and A2 are the amplitudes, and D1 and D2 are the standard deviations of the two sub-
distributions, which should also meet the normalization condition: 
𝐴1 ∗ 𝐷1 + 𝐴2  ∗ 𝐷2 = 1
√2𝜋                                                     (3) 
kmol1 and kmol2 are the two mean spring constants of the integrin-ligand complex which 
correspond respectively to the bent and extended conformation of the integrin.  
Statistical analysis 
All data are presented as mean ± SEM. Differences were determined by t-test. For group 
analysis, two-way ANOVA was used, when significant differences were shown, data was 
subjected to Turkey test for multiple comparison. P values <0.05 were considered significant.  
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III. Results 
The R77H variant of ITGAM, maps to the β-propeller domain and has no effect on Mac-1 
surface expression or activation.  
Since Mac-1 has not been crystalized, the recently reported crystal structure of the active form of 
another closely related integrin CD11c/CD18 (60% homology in the α subunit, (118)) was used 
to model Mac-1 and map the R77 region in its ternary structure (Fig 15A). The R77H resides in 
the β-propeller. The location of binding sites of activation reporter antibodies, functional 
blocking antibodies and controls used in our study are also indicated on the schematic (Fig. 
15A).  
K562 cell lines stably expressing the common (CD11bWT) and the risk-associated variant 
(CD11bR77H) were generated in order to study the functional repercussions of the R77H in 
CD11b-dependent assays. Cells expressing comparable levels of surface CD11b were used (Sup. 
Fig. 3A) and K562 cells that did not express CD11b served as negative controls to confirm 
CD11b specificity. Mn2+ induced activation of CD11b, examined with a CD11b-specific reporter 
antibody (CBRM1/5) that recognizes the I-domain and CD18-specific reporter antibodies 
(Kim127 and MoAb24), was comparable in CD11bWT- and CD11bR77H-expressing cells (Sup. 
Fig. 3B). Similar assays were performed in human neutrophils obtained from healthy genotyped 
donors homozygous for the ITGAM (CD11b) common or risk variant (R77H; rs1143679).  
Surface expression of Mac-1 was comparable between the groups (Sup. Fig. 3C), as was fMLP-
induced exposure of the reporter antibody CBRM1/5 (Sup. Fig. 3D), and rosetting and 
subsequent phagocytosis of complement iC3b-coated RBCs. fMLP-induced expression of 
neutrophil activation markers (i.e. L-selectin shedding and CD16), as well as other surface 
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molecules (i.e. CD11a and CD32) were also normal (Sup. Fig. 3E). Kim127 binding indicates 
integrin extension (119) and internal ligand binding (120), m24 measures headpiece opening 
(121), and iC3b-RBC rosetting requires integrin extension, an open headpiece, hybrid-domain 
swing out (121) and internal ligand binding (120). Thus, together our data suggest that 
CD11bR77H can adopt an extended conformation with open headpiece following direct activation 
with divalent cation (Mn2+ and Mg2+/EGTA) or agonists that induce inside-out signaling (i.e. 
fMLP) and has no effect on overall neutrophil activation. 
R77H impairs ligand binding under shear flow. 
To assess the effect of R77H on the ligand binding capacity of Mac-1, adhesion assays were 
performed under static conditions. Equivalent binding of CD11bWT and CD11bR77H K562 cells to 
an iC3b coated surface was observed when cells were treated with Mn2+ (Fig 15B). However, 
when activated with Mg2+/EGTA, CD11bR77H cells showed a significant defect in their capacity 
to bind.  
In contrast, CD11bR77H-bearing cells were significantly impaired in their capacity to bind iC3b or 
ICAM-1 under shear flow, in the presence of either divalent cation Mn2+ or Mg2+ (Fig. 15C).  
Under Mn2+ conditions, all βI-domain metal sites (MIDAS, ADMIDAS and LIMBS) are 
occupied with Mn2+ and the βI-domain moves to the active state. The open/active βI-domain 
increases the internal ligand flickering and moves the αI-domain to the open/high affinity state. 
Under static conditions, the high ligand density coupled with the active αI-domain maximizes 
the on-rate (but not the off-rate) thus bypassing the requirement for R77. Adhesion under shear 
flow is a result of on- and off-rate and has a more stringent requirement for optimal integrin-
ligand interactions. Under these conditions, R77/β-propeller mediated integrin allosteric signals 
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is essential for productive adhesion. Following Mg/EGTA, which results in metal coordination 
only at the MIDAS site, the βI-domain also moves to the active state. However, under this 
condition, the R77H mutation prevents the internal ligand from being stably immobilized to the 
αI-βI domain interface. This results in a lower internal ligand on-rate and defective iC3b binding 
under static condition, compared to the CD11bWT Mac-1, which populates its αI-domain into the 
active state and achieves high affinity on-rate and adhesion. 
Blockade of the β-propeller region reduces ligand binding under flow 
Functional blocking antibodies that map to the β-propeller domain and control antibodies (109) 
(Fig. 15A and Sup. Fig. 4) were used to evaluate the contribution of the β-propeller domain to 
integrin mediated adhesion under static and shear flow conditions. Blockade of the β-propeller 
by CBRN1/6 and CBRN3/4 abrogated ligand binding under shear flow, but only partially 
affected adhesion under static conditions, thus recapitulating the effect of the R77H variant (Fig. 
15D, E and  Sup.Table 2). Binding of a control antibody, CBR LFA1/7, had no blocking effect. 
The CBRM 1/32 had the highest blocking ability (Sup. Table 2). As the epitope for this antibody 
is at the interphase between the β-propeller and βΙ subunit, (Fig 15C) it may have its effects by 
disrupting the interaction between these two domains. 
Primary human neutrophils expressing the R77H variant exhibit impaired ligand binding 
only under shear flow  
Human neutrophils from healthy genotyped donors homozygous for the ITGAM (CD11b) 
common or risk variants and non-variant carriers were evaluated in adhesion assays. Neutrophils 
carrying the R77H risk variant had no detectable defects in their capacity to bind iC3b in a static 
adhesion assay upon activation with fMLP (Fig. 15F). However, they showed a significant  
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Figure 15. Analysis of the functional effects conferred by the R77H variant of the human ITGAM gene A) Model of CD11b/CD18, using 
the CD11c/CD18 crystal structure. R77 region is shown by the arrow and epitopes for the mentioned antibodies are also indicated. B) Adhesion 
of K562 cells lacking CD11b (- -), or stably expressing the common (CD11bWT) or risk-associated (CD11bR77H) variants on a complement coated 
surface. CD11b activation was induced with Mg2+/EGTA or Mn2+. Results are presented as percentage of adhered cells relative to cells expressing 
CD11bWT in the presence of Mn2+.  Cumulative data from 6 independent experiments  is shown. C) Adhesion to complement and ICAM-1 of 
Mg2+/EGTA or Mn2+ activated cells under shear flow (0.38 dynes/cm2) was evaluated at the indicated time points. Results are presented as 
percentage of adhered cells relative to cells expressing CD11bWT at 8 min. Cumulative data from 4 (iC3b) and 3 (ICAM-1) independent experi-
ments is shown. D) K562 cells expressing CD11bWT were activated with Mn2+.  Binding to ligand-coated surfaces was assessed in (D) static 
conditions  or (E) under shear flow (0.38dynes/cm2). CBRN1/6 and CBRN 3/4 antibodies were used to block different the β-propeller, and 
CBRLFA1/7 antibody was used as an antibody control. F) Adhesion of fMLP-activated neutrophils over complement (iC3b) was evaluated 
under static conditions. Dotted line represents background binding of cells to a blocked non-coated surface (heat inactivated serum). Cumulative 
data from 4 independent experiments is shown. G) Adhesion of fMLP-activated neutrophils to iC3b under shear flow (0.38dynes/cm2), evaluated 
at the indicated time points. Results are presented as percentage of adhered neutrophils relative to the adhesion of neutrophils from the 
non-carrier control donor at 10 min. Cumulative data from 15 samples is shown. Asterisks indicate the difference in adhesion between cells or 
neutrophils expressing CD11bWT and hCD11bR77H or from non-carriers and carriers (*p<0.05, **p<0.01, ***p<0.001). 
66
67 
 
decrease in ligand binding under shear flow (Fig. 15G), concordant with the results using 
integrin expressing K562 cells stimulated with Mn2+. The variant neutrophils exhibited a 
tendency to reduced velocity, albeit this was not significant but had normal spreading over a 
iC3b coated surface (Sup. Fig. 5A and B) when compared to neutrophils bearing the common 
variant, suggesting the possibility that integrin mediated migration, which requires optimal 
integrin on- and off-rates may be compromised by R77H. Antibodies for the β-propeller domain 
were also evaluated in human neutrophils (Sup. Fig. 4B). As in the K562 cell line, the CBRN1/6 
and CBRN 3/4 significantly inhibited ligand binding under shear flow, but were less effective in 
blocking cell adhesion in the static binding assay (Fig. 15H, I and Sup. Table 2). Ninety percent 
of the samples homozygous for the R77H (rs1143679) variant were also homozygous for the 
other two SLE-associated SNPs (r1143678 and rs1143683); the remaining 10% of the samples 
were heterozygous for these SNPs. However, given the similarity in phenotype of CD11bR77H 
K562 cells and variant carrier human neutrophils we anticipate that R77H is principally 
responsible for the defect in adhesion under flow. 
These results suggest that the β-propeller plays a previously undefined role in ligand adhesion 
under shear flow. The β-propeller domain may facilitate the correct orientation of the 
coordinating residues on the βI domain that are required for its interaction with the α7-helix 
from the α subunit I-domain.   
Separation of α and β subunit tails and integrin extension rescues the R77H binding defect 
To gain insight into how the R77H variant affects ligand binding, CD11bR77H additionally 
containing activating mutations of the β subunit (L132A or V124A) (Sup. Fig. 6A) were tested 
in adhesion assays. These mutations were recently described to stabilize CD11c/CD18 in an open 
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headpiece (“cocked”) and extended state with increased affinity for the internal ligand (120). We 
evaluated whether these mutations restored the capacity to bind to iC3b under shear flow. Wild-
type integrins (CD11bWT/CD18V124A, CD11bWT/CD18L132A) exhibited increased binding to 
complement under flow as predicted from the published report. Cells bearing the CD11bR77H and 
CD18L132A or V124A (CD11bWT/CD18V124A, CD11bWT/CD18L132A) remained significantly 
impaired in their ability to bind ligand under shear flow (Fig 16A). As an alternative mechanism 
to induce activation of Mac-1 I-domain, the small molecule Leukadherin-1 (LA-1), which binds 
to SILEN, a coordination residue in the α I domain (122,123) was used. This molecule is 
reported to promote ligand binding, without inducing global conformational changes (122,123). 
Pretreatment with this molecule (104) did not rescue the capacity of CD11bR77H bearing cells to 
bind iC3b under shear flow (Fig. 16B) but enhanced leukocyte adhesion of CD11bWT was 
induced, as previously described (124). 
These results together with the normal Mn2+ induced binding of reporter antibodies and adhesion 
under static conditions, suggests that the R77H variant does not affect the exposure of the αI-
domain, but rather the transmission of allosteric signals required for the βI-domain to reach full 
activation. In order to test this hypothesis, we evaluated the ability of the CBR LFA1/2 antibody  
(Fig. 15A) that induces the full extension of the integrin and the separation of the α and β 
subunit cytoplasmic tails thus resulting in full integrin activation to rescue the adhesion defect in 
CD11bR77H cells. CBR LFA1/2 rescued the ligand binding defect in CD11bR77H cells (Fig. 16C). 
A genetic approach was undertaken to validate this conclusion. GFFKR is a regulatory sequence 
in the CD11b cytoplasmic tail that stabilizes the integrin in an inactive conformation with 
mutation of this sequence resulting in a constitutively active integrin (125), and the separation of 
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the cytoplasmic tails (97) (Sup. Fig. 6B).  Deletion of GFFKR in CD11bR77H rescued the ability 
of cells to bind ligand under shear flow (Fig. 16D). Therefore, the R77H adhesion defect could 
be overcome by forcing the separation of the cytoplasmic tails using both immunological and 
genetic approaches.  
 
 
The R77H mutation disrupts the ability to generate catch bonds, which is fully rescued by 
CBR LFA1/2 Biomembrane force probe experiments and analyses were performed by Yunfeng 
Chen from Dr. Cheng Zhu’s Laboratory  
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Cell expressing CD11bR77H did not have a defect under static conditions when the on-rate was 
optimized with Mn2+ while under shear flow, CD11bR77H cells exhibited a significant defect, 
which is a measure of the integrin on and off rate. This suggested the possibility that R77H 
affected the integrin off-rate under conditions where mechanical forces were applied. To address 
the potential role of R77 and the β-propeller region in the mechanical reinforcement of integrin 
interactions with ligand we exploited a biomembrane force probe (BFP) (Fig. 17A and B), which 
allows the measurement of single bond interactions. The lifetime of the interaction between 
K562 cells expressing Mac-1 (CD11bWT or CD11bR77H) and immobilized recombinant human 
ICAM-1 was measured under the application of different external forces (Fig. 17C).  
BFP experiments were performed in the presence of Mg/EGTA to keep the cells in a moderately 
activating environment. An adhesion frequency assay between CD11bWT bearing K562 cells and 
ICAM-1 beads was firstly performed with and without CBRM1/29, an inhibitory antibody to the 
αI-domain which blocks the specific binding between Mac-1 and ICAM-1. After CBRM1/29 
was added to the experimental buffer, the adhesion became progressively less frequent, which 
confirmed that the binding to ICAM-1 was largely specific for Mac-1 (Fig. 17D).  
Mechanical regulation of Mac-1-ICAM-1 dissociation was then quantified using the K562 cell 
lines and ICAM-1 beads. The mean lifetimes are plotted against the corresponding forces to 
render the lifetime curves, in which the zero-force lifetimes were derived via the thermal 
fluctuation assay and force-involving lifetimes via the force-clamping assay respectively (Fig.  
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18). For CD11bWT, as force increased, the lifetime first increased along and reached the 
maximum at ~13pN, then decreased, exhibiting a biphasic transition from catch to slip bond 
(Fig. 18A, cyan curve). 
In comparison, the catch-slip trend of CD11bR77H was weakened: the sharp summit in CD11bWT 
transformed into a relatively flat plateau, which not only had the amplitude dropping one-fold 
lower, but also shifted leftwards and resulted in a severe shrinking of the catch regime to 0-5pN 
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only (Fig. 18A, magenta curve). Retained at a similar level in the lower force range, the lifetime 
in the higher force range shifted aggressively downwards from CD11bWT, then finally converged 
with the CD11bWT curve at the highest forces where both lifetime curves approach zero. 
Especially, at ~13pN where CD11bWT reached the highest lifetime of 4s, the sustainability of 
CD11bR77H to associate with ICAM-1 was 3-fold lower (~1s). However, at zero-force CD11bWT 
and CD11bR77H had similar lifetimes, the difference between which was statistically 
insignificant. These results suggested that the R77H mutation disrupts the ability of Mac-1 to 
generate catch bonds. The decline of the catch bond impairs the ability of Mac-1 to sustain its 
associations with ICAM-1 under a higher external force, but is ineffective to the lower-force and 
force-free conditions, which is in strong agreement with the results from the adhesion assays 
above that R77H primarily impairs ligand binding under shear flow. 
 
The addition of the CBR LFA1/2 antibody, rendered a robust catch-slip trend of the lifetime vs 
force for both CD11bWT and CD11bR77H (Fig. 18B). The lifetime of CD11bWT was moderately 
enhanced in all force ranges and realized a maximum amplitude of 6s, which is 0.5-fold higher 
than without the antibody (Fig. 18B, orange curve). This enhancement indicated that a 
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substantial fraction of the CD11bWT was still in the inactive (low-affinity) state. For CD11bR77H, 
the increase of lifetime is mainly reflected at the forces higher than 5pN, which remarkably 
rescued the sharp catch-slip biphasic trend (Fig. 18B, purple curve). To be noted, the two 
lifetime curves nicely overlapped with each other in the whole force range, which indicated the 
impact of the mutation on off-rate was completely overcome by the antibody. As control, CBR 
LFA1/7 antibody, which is known to have no effect on the activity of the integrin, made no 
difference to the lifetime of CD11bR77H, confirming the activating function of CBR LFA1/2 
antibody (Fig. 18B, dark blue curve).  
Plotting of the survival frequency vs lifetime curve clearly showed that binding between Mac-1 
and ICAM-1 adopted two states in the presence of external forces, one with a larger off-rate 
(inactive) and the other with a smaller off-rate (active), which was indicated by the sudden slope 
change in the middle of each line (Sup. Fig. 7A, B). This existence of two binding states was not 
altered by the R77H mutation or the addition of the activating antibody, CBR LFA1/2 (Sup. Fig. 
7C-H). However, the slope of the active state was steeper in the presence of R77H under all 
forces, indicating an increase in the off-rates, which provided an explanation for the catch-bond 
elimination (Sup. Fig. 7C, D). Indeed, the addition of CBR LFA1/2 antibody, which rescued the 
catch-bond in cell expressing CD11bR77H, also reversed the slope change of its active state (Sup. 
Fig. 7G, H). 
Integrin leg separation fully rescued the catch bond, while forced activation of βI domain 
had a partial effect  
Deletion of the regulatory region GFFKR of the α subunit, induces the separation of the integrin 
transmembrane and cytoplasmic domains, which is reported to result in integrin activation via 
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inside-out signaling. The addition of GFFKR deletion to CD11bR77H fully rescued its impaired 
catch-slip trend (Fig. 18C). In fact, the resulting lifetime curve overlapped well with those of 
cells where Mac-1 was activated with the CBR LFA1/2 (Fig. 18C). This suggests a central role 
for leg separation in transmitting allosteric signals within the α-subunit that promotes internal 
ligand binding, a step that is essential for catch bond formation (94). 
In comparison, the addition of another mutation, CD18V124A, which stabilizes the βI domain in an 
active state and strengthens the internal ligand binding, did not increase the peak lifetime of 
CD11bR77H (Fig. 18C). However, the force regime of the “catch” phase was broadened to be 
similar to CD11bWT, which indicated a partial rescue of the catch bond (Fig. 18C). 
The bent/extended conformation correlates with integrin binding 
Based on the results that tail separation and integrin extension induced by the activating antibody 
CBR LFA1/2 both enhanced CD11bWT binding and rescued the CD11bR77H binding defect, we 
assessed whether the overall integrin conformational change played a role in regulating the bond 
lifetime. Spring constants of the Mac-1-ICAM-1 complexes were collected from BFP data and 
summarized as an average for each condition (Fig. 19A). It is reasonable to hypothesize that the 
spring constant of the integrin was mainly determined by the bent/extended conformation, and 
that an integrin adopting the bent conformation is more flexible than extended, which has a 
smaller spring constant. This hypothesis has been proven true in another integrin, LFA-1, which 
has a closely structural resemblance to Mac-1 (114). Based on this hypothesis, a lower spring 
constant would suggest a larger portion of the individual integrins adopt a bent conformation. In 
fact, on average, CD11bR77H possessed a significantly lower spring constant than that of 
CD11bWT. The addition of CBR LFA1/2 increased the spring constants of both CD11bWT and 
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CD11bR77H, which is consistent with its function in triggering integrin extension. Moreover, 
similar to the lifetime difference, the difference between CD11bWT and CD11bWT Mac-1 spring 
constant was also eliminated by the activation with the CBR LFA1/2 antibody (Fig. 19A).  
To quantitatively investigate how the ratio of integrin in bent and extended conformation is 
affected by the R77H mutation and activating antibody, the spring constant distributions were fit 
by a two-summit Gaussian distribution, assuming that the spring constant in bent or extended 
conformers each follows a Gaussian distribution. The means for bent (kbent) and extended 
(kextended) spring constant were pre-set to be identical for all four sets of conditions. According to 
the fitting result, about half (54.04%) of CD11bWT adopted an extended conformation, while 
only a small fraction (19.21%) of CD11bR77H was extended (Fig. 19B). Nonetheless, CBR 
LFA1/2 promoted both CD11bWT and CD11bWT into a much higher level of extension, which 
again eliminated the difference in their extension probability (Fig. 19B). 
The fact that a higher percentile of integrin extension corresponded to generally higher amplitude 
of the lifetime curve makes it reasonable to hypothesize that the extension of the integrin has a 
strong positive correlation with the longevity of the lifetime. To test this hypothesis we randomly 
picked up lifetime events from the above four experiments and collected the lifetime and the 
spring constant of the integrin in each. A linear relationship was used for fitting, which rendered 
a positive correlation, with the slope tested to be significantly non-zero (Fig. 19C). 
All the results above suggested that the full extension of the integrin strongly correlates with 
prolonged bond lifetime.  
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The R77H mutation reduced the binding affinity of Mac-1 at zero-force by decreasing its 
on-rate. 
Adhesion frequency assays were performed to characterize Mac-1 binding to ICAM-1 in the 
force-free condition in the presence of Mg/EGTA (Fig. 20A). By fitting the curve to the two-
dimensional adhesion model, effective affinity and off-rate were calculated (Fig. 20B, C) (115). 
The introduction of R77H to Mac-1 significantly reduced its binding affinity, but did not 
contribute much to the off-rate (Fig. 20B, C). Remembering that affinity is the ratio of on-rate to 
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off-rate, this indicated that R77H reduced the binding affinity via reducing its on-rate. The 
addition of CBR LFA1/2 increased the affinity of both CD11bWT and CD11bR77H, although this 
increase in CD11bWT samples was not statistically significant; meanwhile, it also reduced their 
off-rates to a similar level (Fig. 20B, C). Deletion of GFFKR did not rescue, but further lowered 
the affinity deficiency caused by R77H, while V124A not only rescued the deficiency, but 
increased the affinity to about 1.5-fold that of CD11bWT (Fig. 20B, C). Considering that the 
addition of V124A had minor effects on the off-rate compared to the CD11bR77H single mutation 
and CD11bWT, the affinity increase caused by it again resulted merely from the change in on-
rate. 
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IV. Discussion 
We demonstrate that the SLE-associated variant R77H and the β-propeller region in which it 
resides may contribute to the adoption of a high affinity conformation of the βI-domain and in 
turn the establishment of force-induced catch bonds necessary for promoting adhesion between 
Mac-1 and its ligands under mechanical force. Previous work has suggest that the α-subunit is 
critical for ligand-binding specificity while the β-subunit was the most important for transmitting 
the conformational changes that activate ligand binding and connect to the cytoskeleton. The 
importance of R77H and the β-propeller domain in allosteric signaling provides new roles for the 
α-subunit in allostery transmission and provide a potential mechanism for the reported reduction 
in ligand binding in R77H expressing cells. Force induced regulation of adhesion between 
integrins and their ligands may be provided by shear flow within the vessel wall, by traction 
forces exerted by the actin cytoskeleton and actomyosin contraction in migrating cells and 
potentially by microbes captured by integrins at the cell surface. Our previous work suggests that 
Mac-1 regulates FcγRIIA dependent neutrophil adhesion in the context of immune complex 
deposition as assessed by intravital microscopy and in a model of human SLE sera induced lupus 
nephritis (26). We propose that R77H prevents Mac-1 engagement of its ligand and thus 
alleviates Mac-1 mediated inhibition of FcγRIIA dependent neutrophil recruitment to sites of IC 
deposition. 
Where is the R77H lesion? The equilibrium between integrin states is likely regulated by inside-
out signaling induced by chemokines and ligand binding, which induces incompletely 
understood cellular events that stabilize the open headpiece conformation, promotes full 
extension of the integrin and propagates outside-in signals that link to signal transduction and 
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anchorage to the actin cytoskeleton (Fig. 21). Affinity regulation of ligand binding of integrins is 
a complex process. Proper activation of the I-domain has been proposed to require the interaction 
of an invariant Glutamate residue of the α7 helix from the C-terminal region of the I-domain 
with the MIDAS of the βI-like domain, serving as an internal ligand. This interaction exerts a 
downward pull of the α7 helix, required for placing the βI and subsequently the αI in a high 
affinity state. Based on normal exposure of activation reporter epitopes (CBRM1/5, Kim127 and 
MoAb24), and the failure to rescue the ligand binding defect by the βI activating mutants, that 
increase the affinity of the βI-domain for the internal ligand (L132A and V124A) or LA-1 (an 
αI-domain agonist) suggests that the interaction of the αI- and βI-domains is compromised. This 
could be due to changes in rigidity of the β-propeller structure that consequently affects the 
flexibility of the αI-domain and therefore the flickering of the α-7 helix into the internal ligand 
binding pocket in the βI-domain. Cytoplasmic tail separation, well accepted to promote full 
integrin extension with open head piece and actin anchorage (108,126), may rescue R77H by 
allowing force induced allosteric changes.  
R77H results in a reduction in integrin, on-rate and force-free off-rate. This is associated with an 
increase in the integrin fraction in the bent conformation, which is more flexible (lower stiffness) 
at the expenses of the fraction in the extended conformation, which is less flexibility. R77H also 
alters the force-regulated bond dissociation between Mac-1 and ICAM-1 by suppressing their 
catch bond. Both the catch bond force range and the extent of bond lifetime prolongation are 
reduced, resulting in a left- and down-shifted bond lifetime vs force curve. This resembles the 
change in the lifetime vs force curve of LFA-1 bond with ICAM-1 in the presence of XVA143 
(94). XVA143 is a small molecule antagonist that binds the βI-domain binding site for the 
internal ligand at the α7-helix of the αI-domain. This resemblance suggests that R77H mutation  
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results in a defect in the αI-βI inter domain interaction that also exhibits catch bond behavior 
(94). The βI-domain activating mutation V124A, which places the βI domain in a constitutively 
active state (120), rescues affinity, on-rate, force-free off-rate, and the catch bond force range but 
not the extent of bond lifetime prolongation. While wild-type Mac-1 with a GFFKR deletion 
exhibits an open headpiece with high affinity state as reported, R77H with a GFFKR deletion 
adopts a closed headpiece conformation that remains in a bent low affinity state, which suggests 
an interference of allosteric relay between the αI and βI domain. The GFFKR deletion in the 
context of R77H increases the fraction of bent integrin, as revealed by molecular stiffness 
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analysis, thereby reducing the affinity by reducing on-rate, but not force-free off-rate. Under 
tensile force, however, the GFFKR deletion over rescues, the catch bond defect of the R77H 
mutation. The CBRLFA1/2 antibody increases the affinity by decreasing the force-free off-rate 
of the WT integrin, and rescues the affinity of R77H by decreasing the force-free off-rate. 
CBRLFA1/2 also produces the indistinguishable bond lifetime vs force curves for both CD11bWT 
and CD11bR77H with an enhanced catch bond that has the same force range but greater extent of 
lifetime prolongation. Together, these data suggest that a conformational change in multiple 
integrin domains is required for mechanically regulated binding of the integrin-ligand complex 
that is modulated in part by R77 dependent allosteric transmission to the αI-domain.  
The R77H variant is a fairly common allele in the healthy population (~10% of the population). 
In non-autoimmune conditions, the influence of this variant may be minor, due to the existence 
of many regulatory checkpoints. However, in the context of SLE, where dysfunction of several 
aspects of the immune response occurs simultaneously, the R77H variant of CD11b might play 
an important modulatory role. Since CD11b is expressed on many leukocyte subsets, it can 
participate in several aspects of the disease. CD11b has been suggested to be a negative regulator 
of BCR activity (77), suggesting that when dysfunctional, it may lower the activation threshold 
of B cells. This could have repercussions in the maintenance of tolerance and in the amplification 
of self-reactive responses. Mac-1 can also inhibit the signaling of pro-inflammatory receptors 
(e.g. TLR, IFNαR) (18,19,101,104). However, the precise mechanisms through which Mac-1 
exerts its inhibitory signal are not fully understood. Difficulty comes from a lack of information 
regarding inhibitory signaling events triggered by Mac-1 engagement. Spatial separation of the 
cytoplasmic domain has been suggested as a mechanism by which integrins transduce 
information across the cell membrane (97,98), therefore the proper engagement and transmission 
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of allosteric signals from Mac-1 ligand binding domains to the cytoplasmic tails are necessary to 
establish its potential regulatory roles.  
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Chapter 6. General Conclusions 
 
There is emerging evidence that mechanisms that regulate effector responses to ICs probably 
determine the type of organ damage and its severity in patients with SLE. Our work suggests that 
Mac-1 may protect from tissue injury induced by ICs by modulating FcγRIIA-dependent 
neutrophil recruitment. This is supported by data obtained in two murine models of 
glomerulonephritis induced by circulating IgG immune complexes to lupus antigens. The 
relevance of the protective role of Mac-1 in SLE is further supported by several publications that 
a genetic variant of Mac-1 (R77H), shown to impair its function, confers a risk for SLE (24,25). 
Here we have provided a mechanism through which R77H could alter optimal interaction of 
Mac-1 with its ligands and thus contribute to the pathogenesis of SLE.  
As exemplified in our SLE serum-induced nephritis model, and as previously reported in patients 
with SLE, the mere presence of ICs is not sufficient to induce disease. This observation suggests 
that regulatory mechanisms actively control neutrophil responses to deposited ICs. Our data 
suggests that Mac-1 is involved in this regulation. Whether the inhibition that Mac-1 is 
conferring represents a constant tonic inhibitory signal or is rather initiated upon neutrophil 
activation through FcγRIIA, is still undetermined. The biology of Mac-1 is complex as it can 
generate responses that may be context dependent and seemingly contradictory. It possesses a 
potent pro-inflammatory potential and the capacity to enhance murine FcγR responses and renal 
damage in an acute model of anti-GBM glomerulonephritis (127,128). Although the reasons for 
the differences in the role of Mac-1 needs further investigation, it is important to note that anti-
GBM nephritis is induced by in situ antibody deposition in the glomerulus and is an acute 
response while renal damage in our lupus models requires a longer time period and is promoted 
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primarily by soluble immune complexes that deposit in the glomerulus. Moreover, the negative 
regulatory role of Mac-1 appears to be apparent primarily in the context of human FcγRIIA and 
not the murine FcγRs (26). There are other examples where opposing roles for the same receptor 
exist. The affinity/avidity of FcαR (129) and FcγRIII (72,130) for their ligands (i.e. monomeric 
vs. Ig forming ICs), determines the magnitude of the response and whether the outcome is 
activating or inhibitory (e.g. complete phosphorylation of Syk vs. the activation of inhibitory 
phosphatases and/or partial phosphorylation of Syk). The signaling cascade is also modified by 
the presence of other triggers, for example cytokines, which can differentially promote or inhibit 
responses (e.g. the presence of IFN-γ abrogates the induction of IL-10 by Mac-1 on macrophages 
(18)).  
The role of β2 integrins in neutrophil recruitment was initially appreciated in patients with 
leukocyte adhesion deficiency type I (LAD I), where genetic defects on CD18 impair its 
expression, and therefore its association with the α subunits (i.e. CD11b, CD11a and CD11c). 
Neutrophils from these patients show a significant defect in recruitment to the sites of 
inflammation and chemotaxis. Moreover, a loss of function mutation in Kindlin-3, a cytoplasmic 
adaptor protein required for integrin activation (LAD III), phenocopies many of the defects in 
LAD I patients (131,132). Extensive work to dissect the contributions of each of these integrins 
in the recruitment cascade has been done. Mac-1 contributes to the establishment of firm 
adhesion and crawling on the endothelium. However, the study of knock-out mice have revealed 
that LFA-1 has a dominant role during the recruitment cascade. The interference of its function 
(i.e. by blocking antibodies or CD11a-/- mice) strikingly impedes neutrophil recruitment (133) 
and associated tissue injury (i.e. arthritis and nephritis in the MRL/lpr mice) (20,21). In contrast, 
CD11b deficiency does not consistently result in defects in neutrophil recruitment but in 
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combination with LFA-1 deletion can lead to a further reduction in neutrophil accumulation 
compared to LFA-1 deficiency alone (48,134). On the other hand, neutrophil migration was 
shown to be enhanced in CD11b-/- mice in some cases (133), which can explain the worsening of 
the disease intensity in certain contexts (20,21). 
More recently, Mac-1 activation was shown to decrease inflammation in murine models (124). 
The use of the small molecule LA-1, reduced leukocyte migration, tissue accumulation, and 
injury in vivo (123,124). This was confirmed by in vitro studies that showed that LPS and PMA-
induced migration over a Mac-1 ligand was significantly reduced by the activation of Mac-1 
(123). A possible explanation is that partial Mac-1 activation results in the sequestration of the 
neutrophils at the vessel wall by increasing their adhesion to the inflamed endothelium and thus 
reducing leukocyte infiltration into tissues and associated injury.  
We propose that Mac-1 limits immune complex mediated neutrophil recruitment by regulating 
human FcγRIIA activation in particular. This is based on the observation that in contrast to 
FcγRIIA-expressing mice, Mac-1-/- mice that express murine activating receptors are not 
susceptible to developing SLE serum-induced nephritis despite the equivalent ability of human 
and mouse FcγRs to bind human IgG (15). This suggests that the human single polypeptide 
FcγRIIA containing ITAM may be differentially regulated than the murine FcγR which 
associates with the ITAM–containing γ-chain. There may be differences in the downstream 
pathways engaged by the murine versus the human receptors, a possibility that is supported by 
the much more potent injury observed with human FcγRIIA versus murine FcγRs in a model of 
nephrotoxic nephritis despite similar expression levels of the human and murine receptors (15). 
Macrophages, DC, and B cells are cell types that significantly contribute to the loss of tolerance 
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and to the amplification and perpetuation of the autoimmune response in SLE. FcγRs and Mac-1 
are also expressed on these cell types, so it is possible that the inhibitory functions of Mac-1 can 
also modify the behavior of these cells. The contribution of Mac-1 on each of these cell types 
could be addressed by the use of Mac-1 conditional knock-outs, which are currently not 
available.  
We consider that the model we have generated represents an excellent tool to study the local 
factors that contribute to the development of end organ damage triggered by IC deposition. The 
contribution of molecules expressed on the endothelium and other resident renal cells that might 
be important in the amplification, perpetuation or mitigation of the inflammatory responses, can 
be addressed by generating bone marrow chimeras using bone marrow from mice that express 
FcγRIIA and lack Mac-1, into recipient mice that lack or overexpress a molecule of interest. 
Furthermore, the passive human lupus serum induced nephritis model, which leads to renal 
injury within 14 days could serve as a pre-clinical platform to test potential therapeutics that 
target the effector response in SLE. Our model would be more amenable for screening of 
compounds than the lupus prone strains of mice that develop disease over a 6-9 month period 
that is not synchronized because disease is induced by dysregulation of the adaptive immune 
response. 
GWAS have significantly contributed to the identification of genes that confer risk for complex 
diseases. Over 40 loci have been found to be associated with SLE. The next step is to clarify how 
each of these genes affects the immune response in order to determine how the genetic variant 
contributes to disease.  In contrast to most of the SNPs associated with SLE in the GWAS, the 
the rs1143679 variant of Mac-1 causes a non-synonymous mutation (R77H). Therefore, the 
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functional link between the SNP and the presence of SLE must be explained by a functional 
effect of Mac-1.  
Understanding the mechanisms that contribute to SLE will facilitate the diagnosis and treatment 
of patients. In particular, the identification of the mechanisms that favor or oppose the 
development of renal injury in particular is of great interest since lupus nephritis is a major cause 
of morbidity and mortality in patients with SLE. It is estimated that over 60% of patients will 
develop nephritis during the course of their disease. Even though ICs and complement deposition 
are considered to trigger the effector responses associated with the development of disease, to 
date, most of the attention has been on elucidating the role of T cells and DC in disease 
pathogenesis. The role of neutrophils in lupus nephritis has not been completely established, 
despite reports of neutrophil infiltration during lupus nephritis. Our work suggests that 
modulating neutrophil responses might be a key to controlling the damage to target organs and 
that modulation of human FcγRIIA activity by Mac-1 may serve as a rheostat of neutrophil 
recruitment and cytotoxicity in the context of SLE.  
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